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PURPOSE:	  The	  non-­‐specific	  presentation	  of	  pulmonary	  embolism	  (PE)	  leads	  to	  a	  number	  
of	   diagnostic	   challenges.	   Pleural	   effusions	   in	   particular	   are	   an	   under-­‐recognised	  
complication	   of	   PE	   with	   potentially	   lethal	   consequences.	   This	   study	   assessed	   the	  
diagnostic	   yield	   of	   pulmonary	   embolism,	   frequency	   of	   pleural	   effusions,	   pulmonary	  
hypertension	   and	   abnormal	   parenchymal	   findings	   in	   patients	   undergoing	   CTPA	   for	  
suspected	  PTED.	  	  
METHOD:	   The	  CTPAs	  of	  100	  patients	  performed	  between	  September	  2015	  and	   January	  
2016	   were	   analysed	   retrospectively.	   The	   presence/absence	   of	   the	   above-­‐mentioned	  
radiological	  abnormalities	  were	  documented.	  	  
RESULTS:	   PE	   was	   identified	   in	   37%	   of	   cases.	   Pleural	   effusion	   was	   present	   in	   37,8%,	  
pulmonary	   hypertension	   in	   66,7%	   and	   abnormal	   parenchymal	   findings	   in	   59,5%	   of	   PE	  
positive	   patients	   respectively.	   The	   only	   finding	   significantly	   associated	   with	   PE	   was	  
peripheral	  wedge-­‐shaped	  opacities	  (p=0,019).	  	  
CONCLUSIONS:	  There	  was	  a	  higher	  diagnostic	  yield	  of	  PE	  in	  this	  study	  when	  compared	  to	  
similar	   studies	   conducted	   elsewhere.	   With	   the	   exception	   of	   peripheral	   wedge-­‐shaped	  
opacities,	  pleuro-­‐parenchymal	  abnormalities	  are	  of	  limited	  value	  in	  diagnosing	  PE.	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In	  this	  research	  report,	  and	  as	  far	  as	  possible,	  unnecessary	  jargon	  and	  abbreviations	  have	  
been	  avoided.	  There	  are,	  however,	  some	  abbreviations	  that	  are	  necessary	  due	  to	  their	  
frequent	  use.	  The	  more	  commonly	  used	  abbreviations	  have	  been	  listed	  in	  alphabetical	  
order	  below	  to	  assist	  the	  reader.	  
	   • CI	  -­‐	  confidence	  interval	  
	  
• CMJAH	  -­‐	  Charlotte	  Maxeke	  Johannesburg	  Academic	  
Hospital	  	  
	  
• CTEPH	  -­‐	  chronic	  thromboembolic	  pulmonary	  
hypertension	  
	  
• CTPA	  -­‐	  computerised	  tomographic	  pulmonary	  
angiography	  
	  
• DVT	  	  -­‐	  deep	  vein	  thrombosis	  
	  
• HIS	  -­‐	  hospital	  information	  system	  
	  
• HIV	  -­‐	  human	  immunodeficiency	  virus	  
	  
• IQR	  -­‐	  interquartile	  range	  
	  
• PACS	  -­‐	  picture	  archiving	  and	  communication	  system	  	  
	  
• PE	  -­‐	  pulmonary	  embolism	  
	  
• PTED	  -­‐	  pulmonary	  thromboembolic	  disease	  
	  
• RIS	  -­‐	  radiological	  information	  system	  
	  
• SD	  -­‐	  standard	  deviation	  
	  
• TB	  –	  tuberculosis	  
	  
• V/Q	  scan	  -­‐	  ventilation/perfusion	  scan	  
	  	  






My	   particular	   area	   of	   interest	   is	   respiratory	   radiology.	   During	   my	   daily	   practice	   as	   a	  
radiologist	  at	  Charlotte	  Maxeke	  Johannesburg	  Academic	  Hospital,	  it	  became	  evident	  that	  
a	   large	   number	   of	   Computerised	   tomographic	   pulmonary	   angiograms	   (CTPAs)	   for	  
suspected	   pulmonary	   embolism	   (PE)	   are	   performed.	  Many	   of	   these	   CTPAs	  may	   not	   be	  
indicated,	   and	   as	   radiologists,	  we	   are	   acutely	   aware	  of	   risks	   to	   the	  patient,	   particularly	  
from	   ionising	   radiation	  and	  contrast-­‐induced	   reactions.	  Of	   further	  note	   is	   the	  dearth	  of	  
information	  on	  the	  referral	  form,	  particularly	  around	  clinical	  decision	  rules	  and	  previous	  
imaging.	   My	   colleagues	   and	   I	   frequently	   have	   to	   request	   the	   chest	   radiograph,	   which	  
often	   have	   various	   pleuro-­‐parenchymal	   abnormalities.	   All	   of	   this	   raised	   a	   number	   of	  
questions	   around	   yield	   and	   the	   association	   of	   these	   abnormalities	   with	   PE.	   This	   study	  





Pulmonary	   thromboembolic	   disease	   (PTED)	   is	   a	   common	   clinical	   entity,	  with	   significant	  
morbidity	  and	  mortality	  (1).	  While	  it	  is	  therefore	  imperative	  not	  to	  miss	  the	  diagnosis,	  the	  
use	  of	  Computerised	  Tomographic	  Pulmonary	  Angiography	  (CTPA),	  a	  key	  investigation	  in	  
diagnosing	   pulmonary	   embolism	   (PE),	   is	   not	   without	   risk	   to	   the	   patient.	   Of	   particular	  
concern	  is	  ionising	  radiation	  exposure	  and	  the	  potential	  for	  contrast-­‐related	  reactions	  (2).	  	  
However,	   due	   to	   its	   relatively	   non-­‐specific	   symptoms,	   pulmonary	   embolism	   remains	   a	  
challenge	   to	  diagnose.	   This	  has	   led	   to	   an	  apparent	   increase	   in	   referrals	   for	  CTPA	  and	  a	  
decreasing	  yield,	  raising	  concerns	  for	  patient	  safety	  (3).	  	  
	  
South	   Africa	   is	   not	   immune	   to	   this	   problem,	   and	   in	   fact	   the	   high	   human	  
immunodeficiency	   virus	   (HIV)	   and	   tuberculosis	   (TB)	   rates,	   which	   are	   independent	   risk	  
factors	   for	  PTED	   (4),	   put	   the	  affected	  population	  at	   even	  greater	   risk	  of	  developing	  PE.	  	  
There	   appears	   to	   be	   very	   little	   local	   literature	   regarding	   the	   yield	   rates	   of	   CTPAs	  
performed	   in	   South	   Africa.	   There	   are,	   however,	   several	   studies	   documenting	   the	  
frequency	   with	   which	   pulmonary	   embolism	   is	   detected	   on	   CTPA	   in	   the	   international	  
literature	  (2,	  5).	  Therefore,	  as	  a	  first	  objective,	  this	  study	  assessed	  the	  positive	  yield	  rate	  
for	   PTED	   at	   Charlotte	   Maxeke	   Johannesburg	   hospital	   (CMJAH),	   which	   as	   a	   level	   four	  
hospital,	  should	  be	  best	  placed	  to	  compare	  yield	  rates	  to	  a	  more	  developed	  settings.	  	  
	  
Part	   of	   the	   diagnostic	   challenge	   alluded	   to	   above,	   is	   the	  myriad	   of	   causes	   of	   dyspnoea	  
that	  may	   lead	  the	  clinician	   to	  suspect	   the	  possibility	  of	  PTED.	  One	  such	  cause	   is	  pleural	  




pleural	   effusions	   being	   a	  well-­‐documented	   complication	   of	   PTED,	  with	  multiple	   studies	  
showing	   the	   prevalence	   rates	   as	   high	   as	   one-­‐third	   to	   one-­‐half	   of	   cases	   (6,	   7),	   PTED	  
remains	   an	   under-­‐recognised	   cause	   of	   pleural	   effusion	   (8).	   As	   prompt	   treatment	   of	  
pulmonary	  embolism	  can	  reduce	  mortality	  rates	  from	  30%	  to	  less	  than	  10%	  (7),	  this	  delay	  
in	   therapy	   may	   have	   dire	   consequences	   for	   the	   patient.	   Not	   only	   is	   there	   increased	  
mortality,	   but	   postponing	   treatment	   of	   the	   pulmonary	   embolus	  may	   also	   result	   in	   the	  
effusion	  becoming	  complicated,	  thereby	  increasing	  patient	  morbidity.	  Once	  again	  there	  is	  
a	  dearth	  of	  literature	  assessing	  the	  prevalence	  of	  pleural	  effusion	  in	  patients	  with	  PTED	  in	  
South	  Africa.	   	  This	  study,	  as	  an	  additional	  primary	  objective,	  assessed	  the	  prevalence	  of	  
pleural	  effusion	  in	  patients	  with	  PE	  in	  the	  local	  setting.	  	  
	  
Another	   significant	   complication	   of	   PTED	   is	   haemodynamic	   instability	   (1).	   The	   clinical	  
impact	   of	   PE	   depends	   on	   the	   degree	   of	   pulmonary	   arterial	   impedance	   as	   well	   as	   the	  
cardiovascular	  functional	  capacity	  of	  the	  patient	  (9).	  The	  higher	  the	  increase	  in	  pulmonary	  
arterial	  pressure,	  the	  greater	  the	  risk	  of	  right	  ventricular	  failure	  and	  ultimately	  death	  (10).	  
Similarly,	  the	  lower	  the	  cardiovascular	  reserve	  of	  the	  patient,	  the	  greater	  the	  impact	  (1).	  
While	   acute	   pulmonary	   hypertension	   and	   right	   ventricular	   failure	   from	  massive	   PE	  will	  
generally	   be	   clinically	   overt,	   often	   acute	   embolic	   events	   are	   missed	   and	   chronic	  
thromboembolic	   pulmonary	   hypertension	   (CTEPH)	   may	   subsequently	   develop.	   While	  
considered	   rare	   –	   estimated	   to	   be	   in	   the	   range	   of	   1-­‐4%	   (11),	   CTEPH	   carries	   significant	  
morbidity	  and	  mortality.	  Consequently,	  radiological	  evidence	  of	  pulmonary	  hypertension	  
in	   a	   patient	   may	   alter	   the	   clinician’s	   treatment	   recommendations	   for	   the	   PE	   and	   also	  




This	   study,	  as	  a	   third	  objective,	  evaluated	   the	  prevalence	  of	  pulmonary	  hypertension	   in	  
the	  local	  setting.	  This	  was	  then	  compared	  to	  studies	  performed	  in	  other	  settings.	  	  
	  
Lastly,	   as	   mentioned	   above,	   there	   are	   a	   number	   of	   conditions	   that	   may	   mimic	   the	  
symptoms	  of	  PE.	  There	  have	  been	  a	  number	  of	   international	  studies	  that	  have	  assessed	  
the	  occurrence	  of	  parenchymal	  abnormalities	  in	  patients	  with	  and	  without	  PE	  (7,	  12).	  	  As	  
a	  final	  objective,	  this	  study	  identified	  abnormal	  parenchymal	  findings	  in	  patients	  with	  or	  
without	  PE	  on	  CTPA,	  and	  evaluated	  if	  there	  were	  any	  significant	  differences	  between	  the	  





2.	  LITERATURE	  REVIEW	  	  
2.1	  Pulmonary	  Thromboembolic	  Disease	  	  
2.1.2	  Definition	  
PTED	   refers	   to	   the	   lodgement	   of	   a	   clot	   in	   a	   pulmonary	   artery,	   with	   subsequent	  
obstruction	   of	   the	   blood	   supply	   to	   the	   lung	   parenchyma.	   As	   PE	   commonly	   arise	   as	   a	  
complication	  of	  deep	  vein	  thrombosis	  (DVT),	  the	  two	  are	  parts	  of	  the	  same	  process	  and	  
better	   thought	   of	   together	   as	   venous	   thromboembolism	   (VTE)	   (13).	   	   PE	   occur	   in	  
approximately	  one	   third	  of	   cases	  of	  DVT,	  while	  70%	  of	  patients	  with	  pulmonary	  emboli	  
show	  concomitant	  DVT	  (14).	  
	  
2.1.3	  Incidence	  and	  mortality	  rates	  
PTED	   is	  a	  common	  clinical	  entity	  with	   the	  overall	  prevalence	  estimated	  to	  be	  60-­‐70	  per	  
100,000	   population	   (1).	   This,	   however,	   is	   thought	   to	   be	   an	   underestimation,	   with	  
asymptomatic	  PTED	  occurring	   in	  up	   to	  40-­‐50%	  of	  patients	  with	  underlying	  DVT	   (1).	  The	  
prevalence	   rates	   are,	   however,	   risk	   dependent,	   with	   certain	   subsets	   of	   the	   population	  
being	  at	  higher	  risk.	  	  
	  
Although	   many	   cases	   are	   asymptomatic,	   PE	   can	   be	   fatal,	   with	   untreated	   acute	   PE	  
mortality	   being	   approximately	   33%	   (1).	   The	   number	   of	   deaths	   in	   Europe	   alone	   is	  
estimated	   to	   be	   around	   200,000	   per	   year	   (15)	   while	   PE-­‐related	   deaths	   in	   the	   USA	   are	  




current	   figures	   with	   respect	   to	   PE-­‐related	   deaths	   in	   South	   Africa	   (personal	  
communication,	  Professor	  Barry	  Jacobson,	  March	  2016),	  although	  according	  to	  the	  South	  
African	  Medical	  Research	  Council,	  there	  were	  2111	  deaths	  in	  2000	  from	  PE	  (17).	  This	  is	  far	  
less	  per	  capita	  than	  that	  of	  the	  USA	  and	  talks	  to	  the	  inaccuracy	  of	  these	  statistics.	  	  
	  
2.1.4	  Pathophysiology	  of	  VTE	  and	  its	  relation	  to	  pulmonary	  hypertension	  
VTE	   is	   intrinsically	   linked	   to	   the	   interaction	   of	   the	   elements	   of	   Virchow’s	   triad	  	  
(hypercoagulability,	   stasis	   and	  endothelial	   damage)	   (18).	   	  Although	   the	  majority	  of	  DVT	  
remain	   confined	   to	   the	   legs,	   as	  mentioned	   above,	   in	   up	   to	   30%	   of	   cases,	   the	   clot	   will	  
dislodge,	   resulting	   in	  PE.	   The	   resultant	   impact	   and	  manifestations	  of	   the	  PE	  depend	  on	  
four	  major	  factors	  (9):	  
• The	   size	   of	   the	   embolism	   -­‐	   and	   hence	   the	   resultant	   degree	   of	   occlusion	   of	   the	  
pulmonary	  vascular	  tree.	  
• The	  patient’s	  pre-­‐existing	  cardiopulmonary	  status.	  
• Chemical	   vasoconstriction	   -­‐	   due	   to	   serotonin	   and	   thromboxane	   from	   platelets	  
adherent	  to	  the	  thrombus.	  
• Reflex	  vasoconstriction	  -­‐	  as	  consequence	  of	  pulmonary	  artery	  dilatation.	  
	  
The	  combination	  of	  these	  factors	  results	   in	  impedance	  to	  pulmonary	  arterial	  circulation,	  
with	   resultant	   pulmonary	   hypertension.	   This	   increase	   in	   afterload,	   together	   with	  
compensatory	   tachycardia,	   not	   only	   reduces	   right	   ventricular	   output	   (and	   ultimately	  
cardiac	   output)	   but	   also	   increases	   strain	   on	   the	   right	   heart.	   This	   may	   result	   in	   right	  




enlargement	  also	  causes	  a	  compressive	  effect	  on	  the	  left	  ventricle,	  further	  decreasing	  left	  
ventricular	  output	  (9).	  Furthermore,	  the	  redistribution	  of	  blood	  flow	  secondary	  to	  the	  clot	  
results	   in	   ventilation-­‐perfusion	   mismatching,	   further	   elevating	   pulmonary	   arterial	  
pressure	  and	  exacerbating	  the	  hypoxaemia	  (19)	  
	  
2.1.5	  Risk	  factors	  	  
Risk	  factors	  for	  VTE	  can	  be	  divided	  into	  patient-­‐related	  (predisposing	  risk)	  and	  procedure-­‐	  
related	   (exposure-­‐related	   risks)	   (20).	   These	   risks	   can	   further	   characterised	   into	   high,	  
moderate	  or	  low.	  This	  risk	  assessment	  is	  imperative	  as	  the	  guidelines	  for	  prophylaxis	  and	  
treatment	  is	  risk	  class	  dependant	  (20).	  This	  risk	  assessment	  is	  expanded	  on	  in	  figures	  2.1	  
and	  2.2.	  	  
Risk assessment 
Predisposing risk factor Relative risk weighting 
Thrombophilia High 
History of VTE High 
Malignancy High 
Drugs, e.g. tuberculosis treatment, thalidomide  
High 
HIV infection High 
Auto-immune disease High 
Advanced age (>60 years) Moderate 
Chronic cardiac insufficiency Moderate 
Obesity (BMI >30 kg/m2) Moderate 
Oestrogen therapy Moderate 
Pregnancy and the postpartum period Low 
Nephrotic syndrome Low 
Varicose veins Low 
 
 
 Figure	  2.1	  Risk	  assessment	  for	  patient-­‐related	  risk	  factors	  (20)	  
Source:	   Jacobson	   BF	   et	   al.	   Venous	   thromboembolism:	   prophylactic	   and	   therapeutic	   practice	   guideline.	  






Figure	  2.2	  Risk	  assessment	  for	  procedure-­‐related	  risk	  factors	  (20).	  	  
Source:	  Jacobson	  B	  et	  al.	  Venous	  thromboembolism:	  prophylactic	  and	  therapeutic	  practice	  guideline.	  South	  
African	  Medical	  Journal	  2013;	  103(4):	  260-­‐7.	  Appendix	  1,	  Risk	  Assessment;	  p267	  	  
	  
Figure	   2.1	   does	   require	   some	   qualification.	   Firstly,	   it	   must	   be	   noted	   that	   although	  
malignancies	   have	   been	   lumped	   into	   a	   single	   risk	   factor,	   certain	   malignancies	   carry	   a	  
higher	  risk	  for	  thrombotic	  disease,	  with	  pancreatic,	  ovarian	  and	  brain	  malignancies	  being	  
associated	   with	   the	   most	   risk	   (21).	   Secondly,	   it	   should	   be	   noted	   that	   the	   risk	   of	  
thrombotic	   events	   with	   thalidomide	   increases	   substantially	   when	   used	   in	   conjunction	  
with	   dexamethasone	   (22).	   Thirdly,	   the	   table	   does	   not	   differentiate	   between	   hormonal	  
replacement	   therapy	  and	   the	  oral	   contraceptive	  pill	  with	   respect	   to	  oestrogen	   therapy.	  
However,	  they	  appear	  to	  have	  similar	  risk	  profiles,	  with	  the	  former	  having	  been	  shown	  to	  
have	  a	  2-­‐6	  fold	   increased	  risk	  of	  thrombotic	  events	  and	  the	   latter	  a	  2-­‐4	  times	   increased	  





2.1.5.1	  Clinical	  Scoring	  Systems	  	  	  
A	  number	  of	  scoring	  systems	  exist,	  using	  clinical	  information	  and	  patient	  risk	  factors,	  as	  a	  
means	  to	  estimate	  pre-­‐test	  probability	  of	  a	  patient	  having	  a	  VTE	  event.	  Two	  such	  scores	  
are	   the	   Geneva	   score	   and	   the	  Wells	   score.	   As	   the	  Wells	   score	   is	   typically	   used	   in	   the	  
setting	  of	  the	  study	  population,	   it	   is	  described	  further.	   In	  1997,	  Wells	  et	  al,	  developed	  a	  
scoring	  system,	  using	  clinical	   information	  and	  risk	  factors	  to	  create	  a	  three	   level	  scoring	  
system	  (24).	  This	  was	   later	  updated	  to	  a	   two-­‐tier	  system	  (the	   ‘modified’	  Wells	  score)	   in	  
2003	  (25),	  which	  assigns	  scores	  to	  seven	  variables	  related	  to	  the	  patient’s	  clinical	  findings	  
as	  well	  as	  risk	  profile	  (25).	  Based	  on	  the	  score,	  a	  pre-­‐test	  probability	  of	  the	  patient	  having	  
a	  DVT	  or	  PE	  is	  assigned	  and	  a	  clinical	  decision	  rule	  (CDR)	  followed.	  This	  is	  expanded	  on	  in	  
Figure	  2.3.	  	  
	  
Figure	  2.3	  Wells	  clinical	  decision	  (26)	  
Source:	  National	  Institute	  for	  Health	  and	  Clinical	  Excellence.	  Venous	  thromboembolic	  diseases:	  the	  
management	  of	  venous	  thromboembolic	  diseases	  and	  the	  role	  of	  thrombophilia	  testing	  2012	  [cited	  2016	  
27th	  February].	  Available	  from:	  www.nice.org.uk/guidance/CG144.	  
Clinical feature Points Patient score 
Clinical signs and symptoms of DVT (minimum 




An alternative diagnosis is less likely than PE 3  
Heart rate > 100 beats per minute 1.5  
Immobilisation for more than 3 days or surgery 
in the previous 4 weeks 1.5 
 
Previous DVT/PE 1.5  
Haemoptysis 1  
Malignancy (on treatment, treated in the last 
6 months, or palliative) 1 
 
Clinical probability simplified scores 
PE likely More than 4 points   




This	  scoring	  system	  has	  been	  further	  simplified	  to	  a	  two-­‐tier	  scoring	  system	  –	  less	  than	  or	  
equal	   to	  4	  points	   and	  more	   than	  4	  points,	   indicating	  an	   ‘unlikely’	   or	   ‘likely’	   probability,	  
respectively	  (25)	  
	  
2.1.6	  Clinical	  presentation	  of	  pulmonary	  embolism	  
Part	  of	  the	  issue	  related	  to	  the	  increasing	  CTPA	  referral	  and	  dropping	  yield	  rate	  is	  the	  non-­‐
specific	  signs	  and	  symptoms	  related	  to	  PE.	  According	  to	  the	  Prospective	  Investigation	  of	  
Pulmonary	  Embolism	  Diagnosis	  II	  (PIOPED	  II)	  trial	  the	  most	  frequent	  presenting	  symptom	  
of	  acute	  pulmonary	  embolism	   is	  new	  dyspnoea	  at	   rest	  or	  on	  exertion	   (79%	  of	  patients)	  
(27).	   Other	   frequent	   symptoms	   included	   pleuritic	   chest	   pain	   (59%),	   cough	   (39%)	   and	  
orthopnoea	  (35%)	  (27).	   	  Less	  common	  symptoms	   include	  wheeze,	  calf	  or	  thigh	  swelling,	  
and	  non-­‐specific	  chest	  pain.	  
	  
Signs	  also	  present	  a	  diagnostic	   challenge	  with	   tachypnoea,	   a	  non-­‐specific	   finding,	  being	  
present	   in	   nearly	   half	   of	   the	   patients	   (27).	   Other	   signs	   include	   tachycardia,	   abnormal	  
findings	  on	  chest	  examination,	  such	  as	  crackles,	  wheezes	  and	  decreased	  breath	  sounds,	  
and	  signs	  of	  DVT	  (27).	  Rarely	  patients	  presented	  with	  cyanosis,	  pyrexia	  or	  diaphoresis.	  
	  
It	   therefore	   becomes	   apparent	   from	   the	   above,	   that	   the	   most	   common	   signs	   and	  
symptoms	   may	   have	   a	   multitude	   of	   causes.	   This,	   without	   combining	   it	   with	   a	   clinical	  
decision	  rule	  such	  as	  a	  Wells	  score,	  could	  account	  for	  the	  excessive	  referral	  and	  decreased	  





2.1.7	  Pleural	  effusions	  in	  PTED	  
PTED	  remains	  an	  under-­‐recognised	  cause	  of	  pleural	  effusion	  (8).	  Pleural	  effusions	  occur	  in	  
around	  half	  of	  patients	  with	  pulmonary	  embolism	  (6).	  According	  to	  international	  studies,	  
this	  prevalence	  is	  higher	  than	  in	  patients	  without	  pulmonary	  emboli	  (28).	  
	  
The	  exact	  pathogenesis	  of	  pleural	  effusions	  arising	  from	  PE	  remains	  unknown.	  However,	  it	  
is	   thought	   to	   be	   related	   to	   increased	   vascular	   permeability	   in	   the	   lungs	   secondary	   to	  
ischaemia	   or	   the	   release	   of	   vasoactive	   cytokines	   (29).	   Another	   proposed	  mechanism	   is	  
that	   it	   relates	   to	   increased	   hydrostatic	   pressure	   due	   to	   increased	   pulmonary	   pressure,	  
which	   results	   in	  an	   increase	  of	   systemic	  venous	  pressure	  at	   the	  parietal	  pleural	   surface	  
(7).	   Irrespective,	   there	   is	   excessive	   interstitial	   fluid,	   which	   traverses	   the	   visceral	   pleura	  
and	  enters	  the	  pleural	  space.	  
	  
From	  a	  clinical	  perspective,	  pleuritic	  chest	  pain	  in	  patients	  with	  pleural	  effusion	  is	  highly	  
suggestive	  of	  underlying	  PE	  (8).	  	  Biochemically,	  the	  vast	  majority	  pleural	  effusions,	  if	  not	  
all,	   are	   exudative	   (6).	   The	   effusion	   itself	   tends	   to	   be	   small	   (less	   than	   one-­‐third	   of	   the	  
hemithorax)	  and	  unilateral	   in	  more	  than	  75%	  of	  patients	   (6).	  According	  to	  Yap	  et	  al	   the	  
majority	  (86%)	  of	  the	  effusions	  tend	  to	  be	  on	  the	  same	  side	  as	  the	  emboli,	  however,	  the	  
location	  and	  the	  number	  of	  arteries	   involved	  do	  not	  predict	  the	  presence	  of	  the	  pleural	  
effusion	  (28).	  
	  
Although	   typically	   the	   pleural	   effusion	   remains	   small	   and	   therefore	   does	   not	   alter	   the	  
clinical	  management	  (28),	  there	  are	  complications	  related	  to	  pleural	  effusion	  which	  may	  




on	  CTPA	  as	  frequently	  as	  20%	  of	  the	  time	  (6).	  Other	  complications	  include	  increasing	  size,	  
or	   contra-­‐lateral	   effusion,	   which,	   particularly	   after	   the	   initiation	   of	   anti-­‐coagulation	  
therapy,	  likely	  represent	  recurrent	  emboli,	  haemothorax	  or	  pleural	  infection	  (6).	  A	  further	  
rare	   complication	   that	   may	   develop	   is	   Dressler’s	   syndrome,	   which	   is	   characterised	   by	  
pericardial	  effusion,	  fever	  and	  increased	  white	  cell	  count	  (6).	  
	  
2.1.8	  Diagnosis	  	  
As	  mentioned	  above,	  pre-­‐test	   clinical	  assessment	   such	  as	  a	  modified	  Wells	   score,	  helps	  
triage	   patients	   into	   those	   likely	   to	   have	   a	   pulmonary	   embolus	   and	   avoids	   unnecessary	  
testing.	   However,	   there	   are	   additional	   investigations,	   both	   non-­‐imaging,	   as	   well	   as	  
imaging-­‐related,	  where	  the	  findings	  may	  support	  a	  diagnosis	  of	  pulmonary	  embolism.	  
	  
2.1.8.1	  Non-­‐imaging	  
Non-­‐imaging	  investigations	  include:	  
• Biochemical	   –	   in	   the	   past	   decade,	   D-­‐dimer	   measurements	   have	   become	  
fundamental	   to	   the	   evaluation	   of	   patients	   with	   suspected	   acute	   pulmonary	  
embolism	   (30).	   This	   test	   measures	   fibrinogen	   degradation	   products	   associated	  
with	  endogenous	  fibrinolysis	  and	  in	  a	  low	  risk	  setting	  has	  a	  high	  sensitivity	  for	  VTE	  
(approaching	   100%)	   (31).	   However,	   this	   test	   has	   a	   low	   specificity	   as	   it	   may	   be	  
elevated	   in	   a	   number	   of	   inflammatory	   diseases,	   in	   cardiac	   and	   renal	   failure,	   in	  
malignancies,	  after	  trauma,	  post-­‐surgery	  (31),	  and	  in	  pregnancy	  (30).	  It	  therefore	  




associated	   with	   elevated	   D-­‐dimer	   levels,	   further	   affecting	   referral	   patterns	   and	  
yield	  rates.	  
• Electrocardiography	   (ECG)	  –	   ECG	   changes	   can	   range	   from	  an	   isolated	   finding	   of	  
tachycardia	   in	  minor	  PE,	   to	   evidence	  of	   right	   ventricular	   strain,	   including	   a	   right	  
bundle	  branch	  block	  and/or	  evidence	  a	  prominent	  S	  wave	  in	  lead	  I	  and	  a	  Q	  wave	  
and	   inverted	  T	  wave	   in	   lead	   III	   in	   a	  patient	  with	  a	   large	  pulmonary	  embolus	   (so	  
called	   S1,Q3,T3	   pattern)	   (31).	   Therefore,	   in	   minor	   PE,	   where	   tachycardia	   is	   the	  
only	  presentation	  on	  ECG,	  there	   is	  once	  again	   low	  specificity,	  contributing	  to	  the	  
diagnostic	  dilemma	  associated	  with	  PE.	  
• Arterial	   blood	  gases	   –	   characteristic	   findings	   are	   a	   reduced	  PaO2	   and	  normal	   to	  
reduced	  PaCO2	   (31).	  However,	   PaO2	  may	  be	  normal	   in	   smaller	  PE	  and	   there	  are	  
many	  causes	  of	  hypoxaemia	  which	  may	  result	  in	  reduced	  PaO2	  (31).	  As	  such,	  this	  
test	  has	  a	  low	  discriminatory	  value	  when	  used	  in	  isolation.	  
	   	  
2.1.8.2	  Diagnostic	  imaging	  
While	  CTPA	  remains	  the	  mainstay	  of	  diagnostic	  imaging,	  and	  will	  be	  discussed	  in	  detail	  in	  
section	   2.2,	   it	   is	   not	   the	   only	   useful	   test	   in	   diagnosing	   pulmonary	   embolism.	   Other	  
investigations	  that	  may	  contribute	  to	  the	  diagnosis	  of	  PE	  include:	  
• Chest	   radiograph	   	   -­‐	   radiographic	   findings	  are	  non-­‐specific	  and	  chest	   radiographs	  
are	   often	   normal	   in	   PE	   (32).	   Findings	   that	   may	   be	   present	   include	   peripheral	  
wedge-­‐shaped	   opacities	   signifying	   pulmonary	   infarction	   (Hampton’s	   hump),	  
oligaemia	  in	  areas	  of	  the	  lung	  affected	  by	  pulmonary	  emboli	  (Westermark’s	  sign),	  
atelectasis	  and	  pleural	  effusions	  (31).	  Chest	  radiographs	  may	  also	  show	  enlarged	  




with	  cor	  pulmonale.	  	  It	  therefore	  becomes	  apparent,	  that	  while	  non-­‐specific,	  chest	  
radiographs	  may	  be	  useful	   in	   finding	   indirect	   signs	  of	   PE,	   discovering	   associated	  
findings,	  as	  well	  as	  identifying	  complications	  of	  pulmonary	  embolism.	  	  
	   Chest	  radiographs	  are	  also	  useful	  to	  exclude	  mimickers	  of	  PE.	  These	   include	   left-­‐
	   sided	   heart-­‐failure,	   pneumothorax	   and	   rib	   fractures	   (31).	   Moreover,	   a	   chest	  
	   radiograph	  is	  necessary	  for	  correct	  interpretation	  of	  a	  Ventilation/Perfusion	  (V/Q)	  
	   scan.	  
• Ventilation/Perfusion	   scan	   -­‐	   as	   V/Q	   scans	   fall	   under	   the	   ambit	   of	   the	   nuclear	  
medicine	   specialist,	   rather	   than	   radiologist,	   and	   have	   largely	   been	   replaced	   by	  
CTPA.	   Thus	   an	   in-­‐depth	   analysis	   of	   V/Q	   scans	   falls	   beyond	   the	   scope	   of	   this	  
research.	  Nevertheless,	  V/Q	  scans	  do	  play	  a	  complimentary	  role	  in	  the	  diagnosis	  of	  
PE	   and	   may	   be	   the	   preferred	   choice	   of	   investigation	   in	   certain	   settings.	   These	  
include	  patients	  with	   renal	   dysfunction	   that	  prohibit	   the	  use	  of	   contrast	   agents,	  
young	  female	  patients	  where	  there	  is	  concern	  over	  breast	  radiation	  and	  where	  the	  
diagnostic	   quality	   of	   CTPA	  may	   be	   poor.	   Examples	   of	   poor/non-­‐diagnostic	   scans	  
include	   those	   with	   significant	   motion	   artefact	   and	   low	   signal	   to	   noise	   ratio	   in	  
morbidly	  obese	  patients	  (33).	  
	  
	   In	  contrast	  to	  CTPA,	  which	  can	  directly	  visualise	  the	  embolus,	  V/Q	  scans	  measure	  
	   the	  consequent	  perfusion	  defect	  resulting	  from	  the	  PE	  (31).	  However,	  unlike	  many	  
	   of	   the	   mimickers	   of	   PE,	   there	   are	   no	   associated	   ventilation	   defects,	   creating	   a	  
	   ‘mismatch’.	  The	  probability	  that	  the	  mismatch	   is	  due	  to	  PE	   is	  then	  stratified	   into	  




	   on	  this,	  an	   informed	  decision	  on	  further	  management	  or	  diagnostic	   investigation	  
	   can	  be	  made.	  	  
• Pulmonary	  angiography	  	  -­‐	  formal	  angiography	  has	  largely	  been	  replaced	  by	  CTPA	  
and	  should	  only	  be	  considered	  when	  other	  investigations	  are	  inconclusive	  as	  they	  
carry	  a	  higher	  risk	  of	  mortality	  (31).	  	  It	  is	  also	  invasive	  and	  tends	  to	  be	  less	  readily	  
available.	  This	  procedure	  requires	  the	  injection	  of	  contrast	  agent	  through	  a	  pigtail	  
catheter	  introduced	  into	  the	  pulmonary	  artery.	  A	  diagnosis	  is	  made	  by	  visualising	  
abrupt	  cut-­‐off	  of	  a	  pulmonary	  vessel	  or	  a	  filling	  defect	  noted	  within	  the	  pulmonary	  
artery.	  	  
• Magnetic	   Resonance	   Pulmonary	   Angiography	   (MRPA)	   -­‐	   one	   of	   the	   primary	  
concerns	   surrounding	   CTPA	   is	   the	   cancer	   risk	   associated	  with	   ionising	   radiation,	  
particularly	  in	  young	  patients.	  MRPA	  may	  provide	  a	  safer	  alternative	  to	  CTPA	  but	  is	  
still	   currently	   beset	   with	   issues	   such	   as	   low	   sensitivity,	   long	   scanning	   times,	  
uncertainty	   over	   which	   is	   the	   optimal	   sequence	   and	   high	   technical	   failure	   rate	  
(34).	  These	  factors	  currently	  limit	  its	  use,	  however,	  it	  may	  become	  more	  beneficial	  
as	  techniques	  improve.	  
	  
2.2	  Computerised	  Tomographic	  Pulmonary	  Angiography	  (CTPA)	  
Due	   to	   its	  high	  sensitivity,	   ready	  availability	  and	  quick	   scan	   time,	  CTPA	  has	  become	  the	  
pre-­‐eminent	   imaging	   investigation	   in	  patients	  with	  suspected	  pulmonary	  embolism	  (15).	  
This	  has	  resulted	  in	  substantially	  increased	  referral	  rates	  over	  the	  last	  decade.	  However,	  




mentioned	   above,	   this	   concern	   revolves	   predominantly	   around	   ionising	   radiation	  
exposure	  and	  contrast-­‐related	  risks,	  in	  particular	  nephrotoxicity	  (2).	  	  
	  
A	  number	  of	  studies	  have	  looked	  at	  yield	  rates	  for	  PE	  on	  CTPA,	  with	  the	  PIOPED	  II	  study,	  
according	  to	  Devaraj	  et	  al,	  reporting	  emboli	   in	  22.6%	  of	  cases	  (15).	  More	  recent	  studies	  
have	  reflected	  even	  lower	  yield	  with	  a	  number	  of	  studies	  showing	  prevalence	  rates	  in	  the	  
region	   of	   9%-­‐16%	   (5,35,36).	   This	   trend	   has	   led	   to	   the	   creation	   of	   pre-­‐test	   probability	  
scores	  with	  a	  view	  to	   improving	  positive	  yield.	  One	  such	  score	   is	  the	  Wells	  score,	  which	  
was	  discussed	   in	  detail	  above.	   It	  has	  been	  shown	  that,	   for	  example,	  a	  negative	  D-­‐dimer	  
assay	  in	  a	  low	  or	  intermediate	  risk	  patient,	  obviates	  the	  need	  for	  further	  investigation	  (2).	  
	  
Referral	  patterns	  are	  not	  the	  only	  issue	  with	  respect	  to	  CTPA.	  Despite	  technical	  advances,	  
non-­‐diagnostic	  scans	  remain	  a	  problem.	  While	  rates	  may	  vary	  from	  centre	  to	  centre,	  non-­‐
diagnostic	   scans	   are	   thought	   to	   be	   in	   the	   order	   of	   5%-­‐10%	   (15).	   This	   poor	   quality	  may	  
relate	   inter	  alia	  to	  patient	  and/or	  technical	  factors	  (33),	  the	  more	  common	  of	  which	  are	  
explored	  further	  below.	  
	  
2.2.1	  Non-­‐diagnostic	  scans	  
A	  number	  of	  technical	  advances	  have	  been	  made	  with	  a	  view	  to	  enhancing	  scan	  quality.	  
Of	  fundamental	  importance	  is	  the	  contrast	  enhancement	  in	  the	  main	  pulmonary	  arteries.	  
This	  is	  indicated	  by	  the	  attenuation	  level,	  which	  is	  measured	  in	  Hounsefield	  units	  (HU).	  A	  
Hounsefield	  unit	  less	  than	  200	  in	  the	  pulmonary	  trunk	  is	  considered	  non-­‐diagnostic	  (37).	  




iodine	  administered,	  but	  also	  to	  the	  timing	  of	  the	  scan,	  such	  that	   it	  coincides	  with	  peak	  
attenuation	  in	  the	  pulmonary	  arteries	  (38).	  One	  way	  of	  achieving	  this	  is	  to	  bolus	  track	  (as	  
do	  the	  CT	  scanners	  at	  Charlotte	  Maxeke	  Johannesburg	  Academic	  Hospital),	  by	  triggering	  
the	   scan	   a	   short	   time	   after	   a	   threshold	   Hounsefield	   value	   is	   reached	   in	   the	   region	   of	  
interest	  (37)	  (in	  this	  case	  the	  pulmonary	  trunk).	  	  
	  
A	   second	   commonly	   encountered	   technical	   issue	   is	   streak	   artefact,	   caused	   by	   dense	  
contrast	   within	   the	   superior	   vena	   cava	   (SVC).	   This	   causes	   obscuration	   of	   the	   right	  
pulmonary	  artery	  and	  upper	   lobe	  arteries.	   This	   artefact	   can	  be	   reduced	  by	   flushing	   the	  
SVC	  with	  a	  saline	  chaser	  (15).	  
	  
Patient	   factors	  may	  also	  result	   in	  sub-­‐optimal	  scan.	  One	  of	   the	  more	  common	  causes	   is	  
overweight	  patients	  which	  results	  in	  a	  decreased	  signal	  to	  noise	  ratio.	  In	  our	  centre,	  this	  is	  
typically	   countered	   by	   increasing	   the	   intensity	   of	   the	   x-­‐ray	   beam	   by	   increasing	   the	  
milliampere	   seconds	   (mAs).	   A	   second	   commonly	   encountered	   patient-­‐related	   issue	   is	  
motion	   artefact	   from	   respiration.	   This	   artefact	   renders	   pulmonary	   embolism	   at	   this	  
anatomic	  level	  indeterminate	  (33).	  Higher	  multi-­‐slice	  scanners	  have	  reduced	  this	  issue	  as	  
they	  scan	  faster,	  reducing	  breath-­‐hold	  time	  required	  by	  the	  patient.	  
	  
2.2.2	  Radiological	  findings	  	  
The	  CTPA	  may	  provide	  both	  direct	  and	  indirect	  evidence	  of	  pulmonary	  emboli.	  Moreover,	  
based	  on	  the	  radiological	  appearance,	  pulmonary	  emboli	  can	  be	  further	  categorised	  into	  




and	  sub-­‐segmental)	  and	  by	  association,	  size,	  as	  well	  as	  degree	  of	  occlusion	  may	  also	  be	  
ascertained	   and	   are	   relevant	   to	   clinical	   impact	   (1)	   and	   management	   decisions.	   The	  
respective	  radiological	  features	  of	  acute	  and	  chronic	  emboli	  are	  expanded	  on	  below:	  
	  
2.2.2.1	  Acute	  pulmonary	  embolism	  
Direct	  signs	  of	  acute	  pulmonary	  embolism	  include:	  
• Complete	  filling	  defect	  –	  complete	  occlusion	  of	  the	  pulmonary	  artery	  with	  failure	  
to	  opacify	  the	  vessel	  lumen.	  The	  diameter	  of	  the	  vessel	  at	  the	  site	  of	  the	  thrombus	  
may	  be	  increased	  due	  to	  impacted	  thrombus	  (39).	  	  
• Partial	   filling	   defect	   –	   the	   thrombus	  may	   be	   central	   or	   eccentric	   and	   forms	   an	  
acute	  angle	  with	  the	  vessel	  wall	   (33).	  When	  central,	   the	  thrombus	   is	  surrounded	  
by	  contrast	  on	  either	  side	  forming	  a	  ‘polo	  mint’	  sign	  when	  seen	  in	  short	  axis	  and	  
‘railway	  sign’	  when	  seen	  in	  long	  axis	  (39).	  
	  
Indirect	  radiological	  findings	  of	  acute	  pulmonary	  embolism	  include:	  
1. Oligaemia	   –	   while	   more	   commonly	   seen	   on	   formal	   angiography,	   occasionally	   a	  
decrease	   in	   vessel	   calibre	   (as	   measured	   against	   adjacent	   bronchi)	   distal	   to	   the	  
thrombus	  may	  be	  seen	  (39).	  	  
2. Mosaicism	   	   -­‐	   non-­‐uniform	   arterial	   perfusion	   can	   manifest	   as	   a	   patchwork	   of	  





2.2.2.2	  Chronic	  pulmonary	  embolism	  
As	   for	   acute	   pulmonary	   emboli,	   there	   are	   both	   direct	   as	   well	   as	   indirect	   radiological	  
findings	  related	  to	  chronic	  emboli:	  
	  
Direct	  findings	  include:	  
• Complete	  filling	  defect	  –	  complete	  occlusion	  of	  the	  vessel,	  which	   is	  smaller	  than	  
adjacent	  vessels	  (33).	  This	  is	  therefore	  in	  contradistinction	  to	  a	  complete	  occlusion	  
from	   an	   acute	   embolus,	   whereby	   the	   affected	   vessel	   may	   be	   increased	   in	  
diameter.	  
• Partial	   filling	  defect	  –	   these	   tend	   to	  be	  eccentric	  and	  crescent-­‐shaped	  and	   form	  
obtuse	  angles	  with	  the	  vessel	  wall	  (33).	  Again	  this	  is	  in	  contradistinction	  to	  acute	  
emboli,	  which	  may	  be	  central	  or	  eccentric	  and	  form	  acute	  angles	  with	  the	  vessel	  
wall.	  Once	  organised,	   the	   thrombus	  may	  also	   cause	   intimal	   irregularities,	  bands,	  
abrupt	  vessel	  narrowing	  and	  webs	  (41).	  
	  	  
Indirect	  findings	  include:	  
• Post-­‐stenotic	   dilatation	   	   -­‐	   post-­‐stenotic	   aneurysmal	   formation	   is	   a	   common	  
manifestation	  of	  chronic	  PE	  (39).	  
• Calcification	  -­‐	  within	  thrombi	  (41).	  
• Signs	   of	   systemic	   collateral	   supply	   –	   collateral	   supply	   arises	   from	   the	   bronchial	  
vessels	  with	  concomitant	  increase	  in	  their	  size	  and	  calibre	  (39).	  





While	   the	  above	  provides	   information	  with	   respect	   to	  diagnosing	  pulmonary	  embolism,	  
the	  role	  of	  the	  radiologist	  extends	  beyond	  just	  identifying	  and	  further	  characterising	  the	  
disease.	   Pivotal	   to	   the	   further	   management	   of	   the	   patient	   is	   the	   presence	   of	  
complications.	   This	   research	   addresses,	   inter	   alia,	   two	   key	   complications	   –	   pleural	  
effusion	  and	  pulmonary	  hypertension,	  which	  are	  reviewed	  below.	  
	  
2.2.2.3	  Pleural	  effusions	  in	  pulmonary	  thromboembolic	  disease	  
A	  pleural	  effusion	   is	   a	  general	   term	   for	   fluid	  within	   the	  pleural	   space	  and	   radiologically	  
one	  cannot	  differentiate	  between	  exudative	  and	  transudative	  effusions.	  CT	  is	  sensitive	  for	  
the	   detection	   of	   small	   amounts	   of	   fluid	   and	   is	   therefore	   useful	   in	   pleural	   effusions	  
secondary	  to	  PE,	  as	  they	  tend	  to	  cover	   less	  than	  one-­‐third	  of	  the	  hemithorax	  (6).	  These	  
effusions	   are	   unilateral	   in	   more	   than	   75%	   of	   patients	   (6),	   with	   the	   majority	   (86%),	  
ipsilateral	  to	  the	  emboli.	  	  
	  
While,	  typically,	  effusions	  remain	  small,	  the	  effusion	  may	  become	  complicated.	  If	  the	  PE	  
remains	   untreated,	   the	   effusion	  may	   become	   loculated.	   These	   loculations	   are	   seen	   on	  
CTPA	  as	  frequently	  as	  20%	  of	  cases	  (6).	  The	  effusion	  may	  also	  increase	  in	  size,	  or	  be	  found	  
on	   the	   contra-­‐lateral	   side,	   which,	   particularly	   after	   the	   initiation	   of	   anti-­‐coagulation	  






2.2.2.4	  Pulmonary	  hypertension	  in	  pulmonary	  thromboembolic	  disease	  
Pulmonary	  hypertension	  is	  defined	  as	  a	  mean	  pulmonary	  arterial	  pressure	  greater	  than	  or	  
equal	   to	   25mm	   Hg	   (42).	   Pulmonary	   arterial	   pressure	   cannot	   be	   directly	   measured	  
radiologically,	   and	   trans-­‐oesophageal	   echocardiography	   (TEE)	   and	   right-­‐heart	  
catheterisation	   remain	   the	   first-­‐line	   and	   definitive	   diagnostic	   tools	   for	   assessing	  
pulmonary	  arterial	  pressures	  respectively.	  Nevertheless,	  imaging	  does	  have	  a	  role	  to	  play,	  
with	   both	   chest	   radiography	   and	   CTPA	   portraying	   findings	   indicative	   of	   pulmonary	  
hypertension.	  
	  
On	  CTPA,	  a	  main	  pulmonary	  artery	  diameter	  of	  29mm	  or	  more,	  measured	  at	  the	  level	  of	  
the	  bifurcation,	   represents	  pulmonary	  hypertension	   (43).	  While	  a	  diameter	  of	   less	   than	  
29mm	  does	  not	  necessarily	  exclude	  pulmonary	  hypertension,	  this	  value	  has	  been	  shown	  
to	   have	   a	   positive	   predictive	   value	   of	   97%	   (43).	   	   Other	   vascular	   signs	   of	   pulmonary	  
hypertension	   include	  a	  segmental	  artery	   to	  bronchus	  ratio	  of	  more	  than	  1:1	   in	   three	  of	  
four	  lobes;	  and	  an	  aorta	  to	  main	  pulmonary	  artery	  ratio	  of	  less	  than	  1:1	  in	  patients	  under	  
the	  age	  of	  50	  years	  (43).	  
	  
2.2.2.5	  Abnormal	  parenchymal	  findings	  on	  CTPA	  
CTPA	  is	  also	  useful	  to	  identify	  additional	  and/or	  alternate	  parenchymal	  findings	  that	  may	  
clinically	  mimic	  PE	  or	  be	   found	   in	   conjunction	  with	  PE.	  A	   study	  by	   Liu	  et	  al	   identified	  a	  
number	   of	   parenchymal	   abnormalities,	   including	   wedge-­‐shaped	   opacities,	   masses,	  
nodules	  and	   consolidation	   (7).	  All	   of	   these	   findings	  were	   found	   to	  be	  more	   common	   in	  
patients	  with	   PE	   than	   in	   those	  without.	   A	   second	   similar	   study,	   however,	   only	   showed	  




3.0	  AIMS	  AND	  OBJECTIVES	  	  
3.1	  Aims	  
This	  aim	  of	  this	  study	  was	  to	  assess	  the	  diagnostic	  yield	  in	  patients	  at	  Charlotte	  Maxeke	  
Johannesburg	  Academic	  Hospital	  undergoing	  CTPA	  for	  suspected	  PTED	  and	  to	  document	  
the	  prevalence	  of	  pleural	  effusion,	  pulmonary	  hypertension	  and	  abnormal	  parenchymal	  
chest	  findings	  in	  patients	  with	  and	  without	  documented	  PTED.	  	  
	  
3.2	  Study	  Objectives	  
The	  primary	  study	  objectives	  were:	  
1. To	  assess	  the	  positive	  yield	  rate	  of	  PTED	  in	  cases	  undergoing	  CTPA	  for	  suspected	  
PTED	  at	  Charlotte	  Maxeke	  Johannesburg	  Academic	  Hospital.	  	  
2. To	  assess	  the	  frequency	  of	  pleural	  effusions	   in	  PE	  positive	  and	  PE	  negative	  CTPA	  
investigations.	  
The	  secondary	  objectives	  were:	  
1. To	  assess	  the	  frequency	  of	  pulmonary	  hypertension	  in	  PE	  positive	  and	  PE	  negative	  
CTPA	  investigations.	  
2. To	  document	   the	   frequency	  of	   abnormal	  parenchymal	  CT	   findings	   in	  PE	  positive	  
and	  PE	  negative	  scans.	  
3. To	  compare	   the	   frequency	  of	  pleural	  effusion,	  pulmonary	  hypertension,	  and	   the	  
frequency	  and	  nature	  of	  abnormal	  parenchymal	  chest	  findings	  in	  patients	  with	  PE	  




4.0	  RESEARCH	  METHODOLOGY	  	  
	  
4.1	  Research	  Paradigm	  
This	  research	  was	  a	  retrospective	  quantitative	  cross-­‐sectional	  study	  of	  CTPA	  reports	  in	  a	  
population	   of	   subjects	   who	   underwent	   CTPA	   for	   suspected	   PTED	   at	   Charlotte	  Maxeke	  
Johannesburg	  Academic	  Hospital.	  
	  
4.2	  Sample	  
The	  study	  population	  comprised	  adult	  patients	  who	  had	  undergone	  a	  CTPA	  at	  CMJAH	  for	  
suspected	   pulmonary	   embolus,	   starting	   in	   January	   2016,	   and	   moving	   in	   reverse	  
chronological	   order	   until	   a	   sample	   size	   of	   100	  was	   reached.	   This	   resulted	   in	   the	   study	  
extending	  back	  to	  September	  2015.	  
 
For	   this	   study,	   the	   sample	   size	   was	   calculated	   by	   estimating	   the	   proportion	   of	   pleural	  
effusions	   in	   the	   study	   group	   at	   0.5.	  Motulsky	   regards	   this	   as	   “a	  worst-­‐case	   assumption	  
that	   may	   overestimate	   the	   needed	   sample	   size.”	   (44).	   Two	   other	   assumptions	   were	   a	  
confidence	  Interval	  of	  95%	  and	  a	  precision	  (margin	  of	  error)	  of	  10%,	  which	  is	  considered	  
reasonable	  (Personal	  communication,	  Professor	  Peter	  Cleaton-­‐Jones,	  February	  2016).	  
	  
Sample	  size	  for	  prevalence	  was	  determined	  using	  the	  formula	  (45):	  







n	  =	  sample	  size,	  	  
Z	  =	  Z-­‐statistic	  for	  the	  chosen	  level	  of	  confidence,	  	  
P	  =	  expected	  prevalence	  or	  proportion	  	  
d	  =	  precision	  	  
 
Once	  the	  equation	  is	  rearranged:	  	  	  	  	  	  	  	  	   N	  =	  4.	  0.5	  (0.5)	  	  	  	  =	  100	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  0.12	  	  	  	  
This	   sample	   size	   was	   then	   checked	   to	   ensure	   that	   it	   was	   adequate	   to	   analyse	   the	  
secondary	   objective	   of	   testing	   for	   differences	   between	   groups	   with	   and	   without	  
pulmonary	   embolism.	   	   As	   this	   comparative	   analysis	   generally	   required	   a	   test	   of	  
association	  for	  2x2	  tables,	  a	  Fisher’s	  exact	  test	  was	  mainly	  used.	  The	  sample	  size	  needed	  
for	   a	   Fisher’s	   exact	   test	   was	   calculated	   by	   a	   Power	   analysis	   using	   G*Power	   analysis	  
programme	   (46).	   For	   the	   detection	   of	   small,	   medium,	   or	   large	   effect	   sizes,	   with	   80%	  
power	   at	   the	   5%	   significance	   level,	   sample	   sizes	   of	   785,	   87	   and	   31,	   respectively,	   were	  
required.	   	   As	   studies	   typically	   aim	   for	   the	   detection	   of	   at	   least	   a	   medium	   effect	   size	  
(Personal	   communication,	   Dr	   Petra	   Gaylard,	   April	   2016),	   should	   it	   exist	   (which	   would	  
require	   a	   sample	   size	   of	   87),	   the	   sample	   size	   of	   100	   chosen	   for	   this	   study	   was	   also	  
adequate	  for	  this	  secondary	  objective.	  
	  
4.2.1	  Inclusion	  criteria	  
All	   patients,	   18	   years	   of	   age	   and	   older,	   at	   CMJAH	   in	   whom	   CTPA	   was	   performed	   for	  





4.2.2	  Exclusion	  criteria	  
1. Patients	  with	  missing	  radiological	  reports.	  
2. Patients	  in	  whom	  the	  reporter	  could	  not	  ascertain	  whether	  there	  were	  pulmonary	  
emboli	  due	  to	  non-­‐diagnostic	  scans	  or	  similar	  technical	  issues.	  
	  
4.3	  Materials	  and	  Methods	  
Ethics	   approval	   was	   obtained	   from	   the	   Human	   Ethics	   Research	   Council	   (Medical)	   (see	  
Appendix	  A).	  The	  existing	  database	  of	  all	  patients	   that	  have	  undergone	  CTPA	  at	  CMJAH	  
was	  accessed.	   	  The	   reports	  conforming	   to	   the	   inclusion	  criteria	  were	   retrieved,	  and	   the	  
relevant	  data,	  where	  available	   (as	  per	  Appendix	  B:	  Data	  collection	  sheet),	  was	  captured	  
by	   the	   author	   onto	   an	   excel	   spreadsheet.	   Studies	   that	  met	   the	   exclusion	   criteria	  were	  
excluded	  and	  substituted	  with	  an	  additional	  CTPA	  study	  in	  order	  to	  keep	  the	  sample	  size	  
at	  100.	  The	  patient	  data	  was	  anonymised	  by	  ascribing	  a	  random	  code	  to	  each	  patient.	  The	  
key	  to	  this	  code	  is	  only	  available	  to	  the	  researcher	  and	  supervisors.	  	  
	  
The	  CTPA	  studies	   included	  were	  done	  on	  either	   the	  64-­‐slice	  or	  128-­‐slice	  Multi	  Detector	  
Computerized	   Tomography,	   Phillips	   imaging	   system	   at	   Charlotte	  Maxeke	   Johannesburg	  
Academic	  Hospital.	  The	  technical	  parameters	  are	  as	  follows:	  
• 128-­‐Slice	   scanner	   -­‐	   The	   iodinated	   contrast	   material,	   Jopamiron	   (iodine	  
concentration	  of	  370mg	  per	  millilitre)	   is	   injected	  at	  a	  rate	  of	  3	  –	  3.5ml/s	  with	  no	  
bolus	   tracking.	   The	   region	   of	   interest	   is	   applied	   at	   the	   centre	   of	   the	   pulmonary	  




increased	  in	  patients	  with	  higher	  body	  mass	  indices),	  pitch	  of	  0.891,	  slice	  thickness	  
of	   1mm	   and	   detector	   collimation	   of	   0.625mm	  was	   used.	   The	   rotation	   speed	   is	  
0.5s.	  
• 64-­‐Slice	   scanner	   -­‐	   The	   iodinated	   contrast	   material,	   Jopamiron	   (iodine	  
concentration	  of	  370mg	  per	  millilitre)	   is	   injected	  at	  a	  rate	  of	  3	  –	  3.5ml/s	  with	  no	  
bolus	   tracking.	   The	   region	   of	   interest	   is	   applied	   at	   the	   centre	   of	   the	   pulmonary	  
trunk.	   A	   tube	   voltage	   of	   100kV	   with	   a	   baseline	   tube	   current	   of	   10mAs	   (this	   is	  
increased	  in	  patients	  with	  higher	  body	  mass	  indices),	  pitch	  of	  0.798,	  slice	  thickness	  
of	   1mm	   and	   detector	   collimation	   of	   0.625mm	  was	   used.	   The	   rotation	   speed	   is	  
0.5s.	  
	  
4.4	  Data	  Collection	  
The	  CTPA	  reports	  of	  the	  study	  group	  had	  the	  following	  data	  collected	  as	  per	  the	  attached	  
data	  collection	  sheet	  (see	  appendix	  A):	  
• Presence	  or	  absence	  of	  pulmonary	  emboli.	  	  
• Presence	  or	  absence	  of	  pleural	  effusions.	  
• Presence	   or	   absence	   of	   radiological	   evidence	   of	   pulmonary	   hypertension	   (as	  
indicated	   by	   a	  main	   pulmonary	   artery	  measurement	   of	   29mm	  or	   greater	   at	   its	  
bifurcation).	  
• Presence	   or	   absence	   of	   abnormal	   parenchymal	   findings,	   specified	   under	   the	  
following	  headings:	  	  
o Wedge-­‐shaped	  opacification	  (likely	  indicative	  of	  a	  pulmonary	  infarct)	  






In	  order	  to	  provide	  a	  more	  comprehensive	  study,	  the	  following	  data	  were	  also	  captured,	  
where	  available:	  
• Pleural	  effusion	  characteristics,	  including	  laterality	  and	  size	  	  
• Age	  and	  gender	  
• Risk	  factors	  (as	  per	  Wells	  score	  criteria)	  
• Wells	  score	  
• Presence	  or	  absence	  of	  a	  raised	  D-­‐dimer	  level	  
• Human	  immunodeficiency	  virus	  (HIV)	  status	  
	  
4.5	  Reliability	  and	  Validity	  
CTPAs	  have	  both	  a	  high	  sensitivity	  and	  specificity	  for	  detecting	  PE	  (38).	  Virtually	  all	  CTPAs	  
at	  CMJAH	  are	  performed	  with	  standard	  technical	  parameters	  that	  enhance	  the	  reliability	  
of	  these	  studies.	  	  
	  
4.6	  Bias	  and	  Assumptions	  
South	  Africa	  not	  only	  has	  a	  higher	  prevalence	  of	  HIV	  infection,	  which	  will	  results	  in	  a	  two-­‐	  
to	  ten-­‐fold	  increased	  risk	  of	  VTE	  (4),	  but	  also	  presents	  with	  an	  array	  of	  pathology	  that	  can	  






There	   is	  also	   inter-­‐observer	  variability	  associated	  with	  diagnosing	  PE.	   In	  order	  to	  reduce	  
this	   inter-­‐observer	   variability,	   only	   the	   consultant	   radiologist’s	   report,	   or	   review	   of	   the	  
registrar	  report	  (if	  done	  on	  call	  after	  hours),	  was	  used.	  It	  is	  assumed	  for	  the	  purposes	  of	  
this	  research	  that	  the	  consultant	  radiologist’s	  findings	  were	  correct.	  	  
	  
Furthermore,	  as	  data	  was	  collected,	  it	  became	  apparent	  that	  missing	  information	  resulted	  
in	  certain	  limitations.	  Therefore	  assumptions	  needed	  to	  be	  made	  and	  criteria	  followed	  for	  
certain	  variables	  as	  necessary.	  These	  included:	  
• Pulmonary	  embolus	  –	  pulmonary	  emboli	  were	  considered	  present	   if	  assessed	  as	  
such	  in	  the	  report,	  irrespective	  whether	  central	  or	  peripheral.	  	  
• Pleural	  effusion	  -­‐	  if	  the	  presence	  of	  a	  pleural	  effusion	  was	  not	  mentioned,	  it	  was	  
assumed	  to	  be	  absent	  as	  it	  is	  an	  easily	  identified	  finding	  and	  unlikely	  to	  be	  omitted	  
in	  the	  report	  if	  present.	  	  
• Pulmonary	   hypertension	   -­‐	   In	   contradistinction,	   the	   diagnosis	   of	   pulmonary	  
hypertension	   requires	   active	   measurement,	   which	   is	   typically	   performed	   (as	  
evidenced	  by	  88%	  of	  CTPA	  reports	  from	  the	  sample	  documenting	  a	  measurement	  
even	  when	  less	  than	  29mm,	  with	  a	  further	  8%	  of	  reports	  at	  least	  documenting	  the	  
presence	   or	   absence	   of	   pulmonary	   hypertension).	   As	   such,	   if	   no	   mention	   was	  
made	  of	  the	  size	  of	  the	  pulmonary	  artery	  trunk	  and/or	  the	  presence	  or	  absence	  of	  
pulmonary	  hypertension	  was	  not	  mentioned,	  it	  was	  assumed	  to	  be	  missing	  data.	  
• Abnormal	  parenchymal	  findings:	  
o Atelectasis	  –	  during	  the	  course	  of	  data	  collection,	  it	  became	  apparent	  that	  
different	   types	   of	   atelectasis	   were	   mentioned,	   including	   ‘passive’	  




completeness	   sake,	   all	   forms	   of	   atelectasis	   were	   included	   under	   the	  
general	  heading	  of	  ‘atelectasis’.	  
o Mass	  –	   nomenclature	  with	   respect	   to	   nodule	   versus	  mass	   needed	   to	   be	  
addressed.	   The	   strict	   radiological	   definition	   of	   a	  mass	   is	   a	   lesion	   greater	  
than	  3cm,	  with	   lesions	   less	  than	  this	  being	  termed	  nodules	  (40).	  This	  was	  
strictly	   adhered	   to.	   Therefore,	   if	   there	  was	   at	   least	   one	  mass	   lesion	   that	  
measured	  3cm	  or	  more,	  it	  was	  included	  as	  a	  mass,	  even	  if	  termed	  a	  nodule	  
in	   the	   report.	   If	   there	  was	   no	  measurement	   given,	   it	   was	   taken	   at	   face-­‐
value	   that	   a	   ‘mass’	  was	   a	  mass	   and	   a	   ‘nodule’	   (irrespective	   if	   solitary	   or	  
multiple)	  was	  a	  nodule.	  	  
• Risk	   factors	   –	   the	  Wells	   scoring	   system	   only	   accounts	   for	   ‘previous	   DVT/PE’	   or	  
‘clinical	  signs	  of	  DVT’.	  There	  were	  cases	  with	  a	  current	  proven	  DVT/PE	  which	  were	  
included	  as	  a	  risk	  factor	  under	  ‘previous	  DVT/PE’	  as	  the	  Wells	  scoring	  system	  does	  
not	  have	  a	  specific	  line	  item	  for	  proven,	  currently	  existing	  PE.	  
	  
4.7	  Data	  Analysis	  	  
Descriptive	  analysis	  of	  the	  data	  was	  carried	  out	  as	  follows:	  	  	  
• Categorical	  variables	  -­‐	  were	  summarised	  by	  frequency	  and	  percentage	  tabulation,	  
and	  illustrated	  by	  means	  of	  bar	  charts.	  	  	  
• Continuous	  variables	  –	  were	  described	  by	  the	  mean,	  standard	  deviation,	  median,	  





Fisher’s	  exact	  test	  was	  used	  to	  assess	  the	  relationships	  between	  categorical	  variables	  and	  
the	  presence/absence	  of	  PE.	  The	   strength	  of	   the	  associations	  was	  measured	  by	   the	  phi	  
coefficient,	  using	  the	  following	  scale	  of	  interpretation:	  
• 0.50	  and	  above	  	  -­‐	  	  high/strong	  association	  
• 0.30	  to	  0.49	  	  -­‐	  moderate	  association	  
• 0.10	  to	  0.29	  	  -­‐	  weak	  association	  
• Less	  than	  0.10	  –	  little,	  if	  any	  association	  
	  
The	   relationship	   between	   continuous	   variables	   and	   the	   presence/absence	   of	   PE	   was	  
assessed	  by	   the	  Student’s	   t-­‐test	  where	   the	  data	  were	  normally	  distributed.	   	  Where	   the	  
data	  were	  not	  normally	  distributed,	  a	  non-­‐parametric	  alternative,	  the	  Wilcoxon	  rank	  sum	  
test	   was	   used.	   	   	   The	   strength	   of	   the	   associations	   was	  measured	   by	   the	   Cohen’s	   d	   for	  
parametric	  tests,	  whilst	  the	  r-­‐value	  was	  used	  for	  the	  non-­‐parametric	  tests.	  	  The	  following	  
scale	  of	  interpretation	  was	  used:	  
• 0.80	  and	  above	  	  -­‐	  large	  effect	  
• 0.50	  to	  0.79	  	  -­‐	  moderate	  effect	  
• 0.20	  to	  0.49	  	  -­‐	  small	  effect	  
• Less	  than	  0.20	  -­‐	  near	  zero	  effect	  
	  
Data	   analysis	   was	   carried	   out	   using	   SAS	   version	   9.4	   for	   Windows.	   A	   5%	   level	   of	  




5.0	  RESEARCH	  RESULTS	  
5.1	  Sample	  Population	  
A	   sample	   of	   100	   CTPAs	   meeting	   the	   inclusion	   criteria	   (and	   not	   meeting	   the	   exclusion	  
criteria)	  was	  used.	  During	  the	  data	  collection	  process,	   four	  CTPAs	  were	  excluded	  due	  to	  
missing	  age	  data	  (therefore	  it	  could	  not	  be	  verified	  that	  these	  patients	  met	  the	  inclusion	  
criteria	  for	  age),	  two	  were	  excluded	  as	  the	  patients	  were	  under	  18	  years	  of	  age,	  and	  one	  
was	  excluded	  as	   it	  was	  called	  non-­‐diagnostic	  (no	  reason	  was	  documented).	  These	  seven	  
excluded	   scans	   were	   replaced	   with	   CTPA’s	   that	   met	   the	   inclusion	   criteria	   and	   did	   not	  
conform	  to	  the	  exclusion	  criteria.	  
	  
5.2	  Demographics	  
Of	  the	  100	  patients	  analysed,	  75	  were	  female	  (75%),	  24	  (24%)	  were	  male,	  and	  in	  1	  patient	  
the	  gender	  was	  unknown	  due	  to	  missing	  data.	  Although	  age	  in	  this	  study	  group	  follows	  a	  
non-­‐normal	  distribution	  and	  therefore	  the	  median	  and	  IQR	  is	  more	  relevant,	   in	  order	  to	  
compare	   to	   other	   studies	   that	   have	   quoted	   only	   the	   mean	   and	   SD,	   both	   have	   been	  
included.	  The	  mean	  age	  of	  the	  group	  was	  49	  years	  (SD	  17).	  The	  median	  age	  of	  the	  group	  






Figure	  5.1	  Age	  distribution	  of	  study	  group	  
	  
5.3	  Diagnosis	  of	  Pulmonary	  Embolus	  
5.3.1	  Yield	  
A	  diagnosis	   of	   pulmonary	   embolism	  was	   confirmed	   in	   37	   cases	   (37%)	   (95%	  Confidence	  
interval:	  27,6%-­‐47,2%).	  There	  was	  no	  evidence	  of	  pulmonary	  embolism	  in	  60	  cases	  (60%),	  
while	   3	   cases	   (3%)	   were	   equivocal	   (no	   definitive	   diagnosis	   of	   PE	   was	   made,	   but	   the	  







5.3.2	  Diagnosis	  of	  pulmonary	  embolism	  by	  gender	  
Two	  female	  and	  one	  male	  scans	  were	  equivocal	  for	  PE,	  while	  one	  scan	  did	  not	  document	  
gender.	  Of	  the	  remaining	  96	  scans,	  37	  were	  PE	  positive,	  of	  which	  28	  (77,8%)	  were	  female	  
and	  8	  (22,8%)	  male.	  As	  shown	  in	  table	  5.1,	  as	  a	  proportion	  per	  gender,	  38,3%	  of	  females	  
and	   34,8%	   of	   males	   were	   PE	   positive.	   There	   was	   no	   statistically	   significant	   difference	  
between	  genders	  for	  those	  with	  and	  without	  PE	  (p=0.81).	  	  
Table	  5.1	  Diagnosis	  of	  pulmonary	  embolism	  by	  gender	  
Gender	  
	   Female	   Male	  
N	   73	   23	  
PE	  negative	   45	   61,6%	   15	   65,2%	  
PE	  positive	  	   28	   38,4%	   8	   34,8%	  
	  
5.3.3	  Diagnosis	  of	  pulmonary	  embolism	  by	  age	  
There	   was	   no	   statistically	   significant	   difference	   in	   the	   age	   of	   those	   with	   and	   without	  
pulmonary	  embolism	  (p=0,49).	  The	  mean	  age	   for	   the	  positive	  group	  was	  49,2	  years	   (SD	  
17,1	  years)	  and	  the	  negative	  group	  46,1	  years	  (SD	  16,8	  years).	  The	  median	  age	  was	  52,5	  
years	   (IQR	   31-­‐62,5	   years)	   and	   47	   years	   (IQR	   32-­‐62	   years)	   for	   the	   positive	   and	   negative	  
groups	  respectively.	  This	  is	  reflected	  in	  Table	  5.2.	  	  
	  




PE	  negative	   PE	  positive	  
N	   60	   37	  
Mean/SD	   49,2	   17,5	   46,1	   16,8	  





5.4	  Pleural	  Effusion	  and	  Pulmonary	  Embolism	  
Overall	  40	  patients	  (40%)	  had	  an	  identifiable	  pleural	  effusion	  on	  CTPA.	  Of	  the	  60	  patients	  
with	  no	  pulmonary	  embolism,	  26	  (43,3%)	  had	  pleural	  effusions.	  A	  total	  of	  14	  patients	  out	  
of	  40	  patients	  (37,8%)	  with	  PE	  had	  pleural	  effusions.	  There	  were	  no	  significant	  differences	  
between	   the	   frequency	   of	   pleural	   effusion	   in	   those	   with	   and	   without	   pulmonary	  
embolism	  (p	  =0,67).	  These	  findings	  are	  reflected	  in	  table	  5.3.	  
	  





Of	  the	  14	  PE	  positive	  pleural	  effusions,	  it	  was	  documented	  that	  seven	  were	  bilateral	  and	  
seven	  were	  right-­‐sided.	  Of	  the	  seven	  right-­‐sided	  effusions,	  three	  were	  contralateral	  to	  the	  
side	  of	   the	  PE,	   two	  were	   ipsilateral,	  one	  had	  PE	  evident	  bilaterally	  and	  one	  scan	   report	  
had	   no	   documentation	   of	   the	   side	   of	   the	   PE.	   Six	   of	   the	   14	   PE	   positive	   effusions	   were	  
small,	  three	  were	  documented	  as	  large	  and	  five	  scan	  reports	  did	  not	  comment	  on	  size.	  	  
	  
5.5	  Pulmonary	  Hypertension	  and	  Pulmonary	  Embolism	  
A	   total	  of	  54	  patients	   (54%)	  had	  evidence	  of	  pulmonary	  hypertension	   (main	  pulmonary	  
artery	   of	   greater	   than	   29mm),	   42	   patients	   (42%)	   showed	   no	   radiological	   evidence	   of	  
pulmonary	  hypertension,	   and	   in	  4%	   the	  data	  were	  missing.	   The	  main	  pulmonary	  artery	  
(PA)	  measured	  more	  than	  29mm	  in	  32	  out	  of	  60	  PE	  negative	  patients	  (53,3%)	  and	  22	  out	  
Pleural	  Effusion	   Overall	   PE	  negative	   PE	  positive	  
N	   100	   60	   37	  
Yes	   n	  /	  %	   40	   40,0%	   26	   43,3%	   14	   37,8%	  




of	  37	  PE	  positive	  patients	   (66,7%).	  While	  the	  percentage	  appeared	  higher	   in	  PE	  positive	  
patients,	  the	  difference	  was	  not	  significant	  (p=0,27).	  These	  findings	  are	  indicated	  in	  Table	  
5.4.	  	  
	  




5.5.1	  Main	  pulmonary	  artery	  size	  
The	  main	  pulmonary	  artery	   size	  distribution	   followed	  a	  non-­‐normal	  distribution,	  and	  as	  
such,	  the	  median	  and	  interquartile	  range	  were	  reported.	  	  The	  overall	  median	  size	  of	  the	  
main	  pulmonary	  artery	  was	  30	  mm	  (IQR	  27	  to	  35,4	  mm).	  The	  median	  size	  of	  the	  main	  PA	  
was	   30mm	   (IQR	   26,4-­‐34,6)	   and	   30,3mm	   (IQR	   27,5-­‐37)	   in	   the	   PE	   negative	   and	   positive	  
groups	   respectively.	   These	  differences	  were	  not	   significant	   (p=0,30).	   The	  distribution	  of	  
the	  data	  is	  shown	  in	  Figure	  5.2.	  	  
	  	  	  
Pulmonary	  
hypertension	   Overall	   PE	  negative	   PE	  positive	  
N	   100	   60	   37	  
Yes	   n	  /	  %	   54	   54,0%	   32	   53,3%	   22	   66,7%	  





Figure	  5.2	  Distribution	  of	  the	  size	  of	  the	  main	  pulmonary	  artery	  	  
	  
5.6	  Abnormal	  Parenchymal	  Findings	  	  
At	  least	  one	  parenchymal	  CT	  abnormality,	  as	  per	  the	  data	  points,	  was	  detected	  in	  59%	  of	  
cases.	   The	   most	   common	   parenchymal	   finding	   was	   consolidation/ground-­‐glass	  
opacification	   (41%),	   followed	   by	   atelectasis	   (19%).	   Wedge-­‐shaped	   opacification	   and	  






Figure	  5.3	  Prevalence	  of	  parenchymal	  abnormalities	  	  	  
	  
Overall,	   58,3%	   of	   PE	   positive	   and	   59,5%	   of	   PE	   negative	   patients	   showed	   parenchymal	  
abnormalities,	  which	  was	  not	  significantly	  different	  (p=>0,99).	  When	  these	  parenchymal	  
abnormalities	   were	   looked	   at	   independently,	   only	   peripheral	   wedge-­‐shaped	   opacities	  
were	  more	   common	   in	   the	   PE	   group	   compared	   with	   the	   non-­‐PE	   group	   (four	   vs.	   zero;	  
p=0,019;	   phi	   =	   0,26).	   While	   consolidation/Ground-­‐glass	   Opacification	   and	   atelectasis	  
appeared	  to	  be	  more	  common	  in	  the	  PE	  positive	  group	  (45,9%	  versus	  38,3%	  and	  18,9%	  
versus	   18,3%	   respectively)	   and	   masses	   were	   ostensibly	   more	   common	   in	   the	   non	   PE	  
group	   (5%	   versus	   0%),	   none	   of	   these	   findings	  were	   shown	   to	   be	   significantly	   different.	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Table	  5.5	  Abnormal	  parenchymal	  findings	  and	  pulmonary	  embolism	  	  
	  
*With	  the	  exception	  of	  peripheral	  wedge-­‐shaped	  opacities	  (p=0,019),	  there	  were	  no	  significant	  
differences.	  
5.7	  Risk	  Factors,	  Wells	  score,	  D-­‐Dimer	  levels	  and	  HIV	  Status	  
While	  not	  defined	  as	  objectives,	  the	  researcher	  collected	  individual	  risk	  factors	  (as	  per	  the	  
Wells	   score),	   overall	   Wells	   score,	   D-­‐dimer	   values,	   and	   HIV	   status,	   where	   available.	   In	  
terms	  of	  risk	  factors	  (as	  per	  Wells	  scoring	  system),	  5	  cases	  had	  clinical	  evidence	  of	  DVT,	  
there	  was	  a	  tachycardia	  in	  16	  cases	  (although	  it	  was	  mostly	  unspecified	  if	  the	  heart	  rate	  
was	   above	   100	   beats/min	   as	   per	   Wells	   score)	   and	   a	   history	   of	   recent	  
surgery/immobilisation	  was	  given	  in	  21	  of	  the	  100	  cases.	  There	  was	  a	  previous	  DVT/PE	  or	  
current	  proven	  DVT/PE	  in	  9	  cases,	  malignancy	  was	  mentioned	  in	  15	  of	  the	  100	  cases	  and	  
haemoptysis	   was	   documented	   once.	   The	   remaining	   cases	   contained	   missing	   data	   and	  
therefore	  this	  did	  not	  allow	  for	  any	  meaningful	  statistical	  analysis.	  
	  
	  
Variable*	   Category	   PE	  negative	   PE	  positive	  
N	   	   60	   37	  
At	  least	  one	  
parenchymal	  
abnormality	   	   35	   58,3%	   22	   59,5%	  
Wedge-­‐
shaped	  
opacification	   Yes	   n	  /	  %	   0	   0,0%	   4	   10,8%	  
	   No	   n	  /	  %	   60	   100,0%	   33	   89,2%	  
Consolidation/
GGO	  
Yes	   n	  /	  %	   23	   38,3%	   17	   45,9%	  
No	   n	  /	  %	   37	   61,7%	   20	   54,1%	  
Atelectasis	   Yes	   n	  /	  %	   11	   18,3%	   7	   18,9%	  
No	   n	  /	  %	   49	   81,7%	   30	   81,1%	  
Mass	   Yes	   n	  /	  %	   3	   5,0%	   0	   0,0%	  




The	  overall	  Wells	  score	  was	  only	  documented	  in	  10%	  of	  patients,	  and	  ranged	  from	  3,5	  to	  
7,5.	   Three	   of	   these	   cases	   had	   pulmonary	   emboli	   and	   had	   Wells	   scores	   of	   3,	   7	   and	   7	  
respectively.	  The	  marked	  absent	  data	  precluded	  any	  meaningful	  analysis.	  	  
	  
	  The	  D-­‐dimer	  level	  was	  raised	  in	  30	  out	  of	  the	  100	  patients,	  with	  the	  vast	  majority	  of	  the	  
remaining	   cases	   having	   no	   recorded	  D-­‐dimer	   level,	   nor	   indication	   as	   to	  whether	   it	  was	  
elevated	  or	  not.	  Of	  these	  30	  patients,	  11	  had	  concomitant	  PE.	  Once	  again	  the	  lack	  of	  data	  
did	  not	  allow	  for	  further	  consequential	  analysis.	  	  
	  
In	   terms	  of	  combining	   the	  D-­‐Dimer	  with	  Wells	   score,	  as	  would	  be	  done	  when	   following	  
clinical	  decision	  rules,	  only	  3	  cases	  had	  both	  a	  documented	  raised	  D-­‐dimer	  level	  and	  Wells	  
score.	   Of	   these,	   one	   had	   pulmonary	   embolism	   (Wells	   score	   3,5).	   The	   remaining	   two	  
patients,	   although	   reported	   as	   PE	   negative,	   did	   have	   significant	   risk	   factors	   for	   PE	   as	  
evidenced	  by	  wells	  scores	  of	  6	  and	  7,5	  respectively.	  	  	  
	  
The	  HIV	  status	  was	  given	  as	  positive	  in	  19	  cases	  and	  negative	  in	  two	  cases.	  Of	  the	  19	  HIV	  
positive	   patients,	   9	   had	   pulmonary	   emboli,	   while	   one	   of	   the	   two	   documented	   HIV	  
negative	  patients	  had	  a	  PE.	  The	  rest	  failed	  to	  mention	  HIV	  status.	  Therefore	  similarly,	  the	  






5.8	  Overall	  CTPA	  Findings	  	  
Eighty-­‐eight	  scans	  (88%)	  had	  at	  least	  one	  CTPA	  abnormality.	  Pulmonary	  hypertension	  was	  
the	   most	   common	   finding	   (54%),	   followed	   by	   consolidation	   and/or	   ground-­‐glass	  
opacification	  (41%).	  The	  third	  most	  common	  finding	  was	  pleural	  effusion	  (40%),	  followed	  
by	   pulmonary	   embolism	   (37%).	   Atelectasis	   (19%),	   masses	   (4%)	   and	   wedge-­‐shaped	  
opacifications	  (4%)	  were	  less	  commonly	  seen.	  	  The	  prevalence	  of	  each	  abnormal	  finding	  is	  
indicated	  Figure	  5.	  4*.	  	  
	  
Figure	  5.4	  Prevalence	  of	  CTPA	  findings	  	  
*	  Missing	  data	  with	  respect	  to	  PE	  represents	  equivocal	  scans	  	  
	  
In	   terms	  of	   the	  PE	  positive	   group,	   81,7%	  had	  at	   least	   one	  CTPA	  abnormality	   (excluding	  
PE).	  This	  figure	  was	  81,1%	  in	  the	  PE	  negative	  group.	  There	  was	  no	  significant	  difference	  
between	  the	  two	  groups	  (p=>0,99).	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Computerised	  tomographic	  pulmonary	  angiography	  (CTPA)	  has	  become	  the	  pre-­‐eminent	  
investigation	  for	  diagnosing	  pulmonary	  embolism	  (PE).	  	  However,	  it	  is	  not	  without	  risk	  to	  
the	   patient	   and	   increasing	   referral	   rates	   and	   decreasing	   yields	   have	   raised	   cause	   for	  
concern.	   Part	   of	   the	   reason	   for	   this	   increasing	   referral	   is	   the	   diagnostic	   challenge	  
presented	   by	   a	   myriad	   of	   conditions	   that	   may	   mimic	   pulmonary	   embolism.	   CTPA,	  
however,	   is	   not	   only	   useful	   in	   diagnosing	   pulmonary	   embolism	   but	   is	   also	   helpful	   in	  
identifying	   additional	   and/or	   alternate	   findings.	   These	   findings	   encompass	   pleural	   and	  
vascular	  abnormalities	  such	  as	  pleural	  effusions	  and	  pulmonary	  hypertension,	  as	  well	  as	  
parenchymal	  findings.	  The	  latter	   include	   inter	  alia	  masses,	  consolidation	  and/or	  ground-­‐
glass	  opacification,	  wedge-­‐shaped	  opacifications	  and	  atelectasis.	  	  
	  
This	   study	   looked	   at	   the	   above	   elements.	   	   Each	   section	  of	   the	   results	   chapter	   above	   is	  
analysed	   in	   this	   chapter	   with	   a	   view	   to	   comparing	   it	   to	   current	   existing	   literature.	  
Interpretation	   was	   facilitated	   by	   insights	   gained	   and	   knowledge	   garnered	   from	   the	  
literature	  review,	  as	  well	  as	  the	  day-­‐to-­‐day	  knowledge	  of	  the	  researcher.	  	  
	  
6.1	  Demographics	  
The	   female	   to	   male	   ratio	   of	   the	   current	   study	   population	   referred	   for	   CTPA	   was	   3:1.	  
Although	  this	  could	  be	  attributed	  to	  females	  having	  a	  higher	  prevalence	  of	  PE	  than	  males,	  
studies,	   including	   this	   one,	   have	   shown	   no	   gender	   bias	   with	   respect	   to	   pulmonary	  




As	   referral	   is	   predominantly	   based	   on	   clinical	   presentation,	   exploration	   of	   any	   possible	  
gender	   differences	   in	   clinical	   presentation	   is	   warranted.	   The	   International	   Cooperative	  
Pulmonary	   Embolism	   Registry	   (ICOPER),	   showed	   dyspnoea	   to	   be	   more	   common	   in	  
women,	  while	   haemoptysis	   and	   chest	   pain	  were	  more	   common	   in	  men	   (47).	   A	   similar	  
study	  by	  Ebadi	  et	  al	  also	  found	  dyspnoea	  to	  be	  more	  common	  in	  women.	  As	  dyspnoea	  is	  
the	  most	   common	   presenting	   symptom	   of	   pulmonary	   embolism	   (27),	   which	   in	   itself	   is	  
fairly	  non-­‐specific,	  this	  may	  account	  for	  the	  higher	  referral	  rates	  in	  females.	  
	  
As	  previously	  mentioned,	  due	  to	  age	  following	  a	  non-­‐normal	  distribution,	  the	  median	  and	  
interquartile	   range	   are	   more	   appropriate	   measures	   than	   the	   mean	   and	   standard	  
deviation.	   However,	   in	   order	   to	   compare	   the	   findings	   to	   other	   studies,	   which	   typically	  
quote	  mean	  and	  standard	  deviation,	  the	  latter	  has	  also	  been	  included	  in	  this	  study.	  	  
	  
The	  mean	  age	  of	  the	  group	  was	  49	  years	  (SD	  17	  years).	  The	  median	  age	  of	  the	  group	  was	  
49	   years	   (IQR	   31,5	   to	   62	   years).	   This	   was	   somewhat	   lower	   than	   international	   studies	  
where	  the	  mean	  age	  was	  approximately	  60	  years	  with	  a	  similar	  standard	  deviation	  to	  this	  
study	  (7,	  47).	  This	  may	  relate	  to	  differences	  in	  risk	  factors,	  such	  as	  a	  higher	  rate	  of	  HIV	  and	  
TB	   infection	   in	   South	   Africa,	   which	   are	   independent	   risk	   factors	   for	   PTED	   (4)	   and	   will	  
typically	   present	   in	   younger	   patients.	   	   This	   appears	   to	   be	   substantiated	   by	   a	   study	   by	  
Bibas	   et	   al,	   which	   showed	   the	   mean	   age	   for	   VTE	   in	   HIV	   positive	   patients	   to	   be	  
approximately	  40	  years	  old,	  which	  is	  20	  years	  earlier	  than	  those	  without	  HIV	  infection	  (4).	  
However,	   this	   could	   not	   be	   confirmed	   in	   the	   current	   study,	   as	   the	   data	   regarding	   risk	  
factors	  for	  PE	   in	  the	  current	  study	  group,	  and	  in	  particular	  that	  related	  to	  HIV	  infection,	  




Further	  analysis	  of	   the	  age	  distribution	  shows	  more	  patients	   to	  be	   in	   the	  60	   to	  70	  year	  
range	   than	   any	   other	   decade,	   despite	   a	   lower	   overall	   group	   mean/median.	   There	   is	  
evidence	   to	   suggest	   that	   incidence	   increases	   with	   age	   (48).	   Although	   there	   are	   fewer	  
people	  in	  the	  70	  years	  and	  above	  age	  groups	  in	  this	  study,	  this	   is	   likely	  a	  result	  of	  there	  
being	  fewer	  people,	  in	  general,	  in	  these	  age	  groups,	  rather	  than	  a	  lower	  prevalence	  rate.	  
This	   increased	   frequency	   of	   this	   older	   group	   may	   then	   reflect	   a	   peak	   in	   a	   population	  
group	  which	  more	   closely	   follows	   the	  demographics	   of	   those	   in	   international	   literature	  
where	   the	   HIV/AIDS	   prevalence	   is	   lower.	   Thus	   we	   possibly	   have	   a	   bimodal	   type	  
distribution,	  with	  different	  age	  values	  in	  HIV	  positive	  and	  negative	  groups.	  This	  once	  again	  
affords	  an	  opportunity	  for	  further	  research	  where	  the	  HIV	  status	  and	  prevalence	  can	  be	  
analysed	  according	  to	  age	  in	  the	  local	  setting.	  	  
	  
6.2	  Diagnosis	  of	  Pulmonary	  Embolus	  
6.2.1	  Yield	  
A	   diagnosis	   of	   pulmonary	   embolism	   was	   confirmed	   in	   37	   cases	   (37%).	   This	   yield	   rate	  
measures	   favourably	  with	  a	  number	  of	   studies	  performed	  elsewhere,	  where	  yield	   rates	  
are	  in	  the	  9%-­‐16%	  range	  (5,35,36).	  Even	  when	  compared	  to	  the	  PIOPED	  study,	  which	  has	  
a	  higher	  yield	  rate	  of	  23%	  (15),	   this	  study	  compares	  positively.	  While	   this	  may	  relate	  to	  
better	   clinical	   assessment,	   with	   the	   lack	   of	   D-­‐dimer	   values	   and	   Wells	   scores	   on	   the	  
referral	   letters	   merely	   a	   documentation	   omission,	   it	   may	   also	   indicate	   that	   clinical	  
decision	   rules	   are	   not	   being	   followed.	   Therefore	   this	   higher	   yield	  may	   be	   due	   to	   other	  




	  One	  possibility	   is	   that	   the	   increased	   risk	   factors,	   particularly	  HIV	   infection	   and	   TB	  may	  
contribute	  to	  a	  higher	  prevalence	  of	  concomitant	  PE	  in	  patients	  presenting	  with	  alternate	  
findings,	  which	  would	  typically	  not	  be	  present	  in	  HIV	  negative	  patients.	  Another	  possible	  
reason	   for	   this	   increased	   yield	   may	   relate	   to	   overcalling	   by	   the	   radiologists.	   A	   future	  
application	  then	  of	   this	  study	  could	   look	  at	   inter-­‐observer	  variability	  among	  radiologists	  
when	  reading	  CTPA’s.	  
	  
6.2.2	  Diagnosis	  of	  pulmonary	  embolism	  by	  gender	  
Although	  75%	  of	  the	  PE	  positive	  patients	  were	  female,	  this	  was	  merely	  a	  function	  of	  three	  
times	   as	   many	   females	   than	   males	   being	   referred	   for	   CTPA’s,	   rather	   than	   any	   true	  
difference	  in	  prevalence.	  When	  analysed	  separately,	  there	  was	  no	  significant	  difference	  in	  
frequency	  by	  gender,	  with	  28	  out	  of	  75	  females	  (37%)	  and	  8	  out	  of	  24	  males	  (33%)	  being	  
PE	  positive.	  This	   is	   in	   line	  with	  other	  studies,	  which	  have	  shown	  the	   incidence	  of	  VTE	   is	  
gender	  neutral	  (47).	  	  
	  
6.2.3	  Diagnosis	  of	  pulmonary	  embolism	  by	  age	  
There	  were	   no	   significant	   differences	   in	   the	   age	   of	   those	  with	   and	  without	   pulmonary	  
embolism.	   There	   is	   a	   dearth	  of	   literature	   comparing	   age	   in	   those	  with	   and	  without	   PE,	  
however,	  the	  lack	  of	  statistical	  difference	  between	  the	  PE	  positive	  and	  negative	  groups	  in	  
the	   current	   study	   is	   concordant	   with	   a	   study	   by	   Liu	   et	   al,	   albeit	   the	   mean	   age	   in	   the	  




6.3	  Pleural	  Effusion	  and	  Pulmonary	  Embolism	  
Pleural	  effusion	  was	  present	  in	  37,8%	  of	  the	  PE	  positive	  group.	  A	  number	  of	  studies	  have	  
shown	   the	   frequency	   of	   pleural	   effusions	   to	   be	   approximately	   50%	   (6,	   49).	   While	   the	  
prevalence	  of	  pleural	  effusion	  has	  shown	  to	  be	  higher	  in	  the	  post-­‐operative	  setting,	  of	  the	  
eight	   patients	   with	   pulmonary	   embolism	   that	   cited	   immobilisation/surgery	   as	   a	   risk	  
factor,	   only	   two	   had	   pleural	   effusions.	   While	   this	   figure	   is	   likely	   inaccurate	   due	   to	  
significant	  missing	  data,	   it	  does	   suggest	   that	   there	  may	  be	  other	   reasons	   for	   this	   lower	  
prevalence	  rate.	  	  
	  
One	  reason	  may	  be	  the	  relatively	  small	  sample	  size	  of	  this	  study	  and	  a	  larger	  study	  may	  
therefore	   yield	   different	   results.	   A	   second	   possibility	   is	   ethnicity.	   The	   previously	  
mentioned	  studies	  were	  performed	  in	  a	  first	  world	  setting,	  where	  the	  demographics	  are	  
likely	   different	   to	   the	   local	   setting.	   Ethnicity	   has	   been	   shown	   to	   have	   a	   bearing	   on	  
prevalence	  rates	  of	  pleural	  effusions	   in	  patients	  with	  PE,	  with	  a	  study	  performed	   in	   the	  
USA	  showing	  Asians	   to	  have	  a	   lower	  prevalence,	  when	  compared	   to	  Caucasian	  patients	  
(50).	  This	  hypothesis	  is	  further	  borne	  out	  by	  the	  fact	  that	  a	  study	  performed	  on	  a	  Chinese	  
population	  also	  showed	  a	  markedly	  lower	  frequency,	  in	  the	  order	  of	  19%	  (7).	  	  	  
	  
Some	   studies	   have	   shown	   pleural	   effusions	   associated	   with	   pulmonary	   emboli	   are	  
typically	   small,	  unilateral	  and	   ipsilateral	   to	   the	  PE	   (6,	  28).	  The	   findings	  of	   this	   study	  are	  
quite	   different,	   showing	   an	   equal	   number	   of	   bilateral	   and	   unilateral	   effusions	   and	   a	  
contralateral	   to	   ipsilateral	   ratio	   of	   3:2	   in	   those	   that	   were	   unilateral.	   The	   size	   findings	  
conformed	  more	   to	   the	   international	   literature,	  with	   six	  of	   the	  14	  PE	  positive	  effusions	  




remainder).	   The	   small	   numbers	   may	   account	   for	   these	   differences	   but	   the	   greater	  
bilaterality	   should	   be	   noted	   and	   may	   merely	   reflect	   the	   lack	   of	   sensitivity	   of	   CTPA	   in	  
identifying	  sub-­‐segmental	  pulmonary	  emboli	  (6).	  
	  
As	  a	  secondary	  objective	  this	  study	  also	  compared	  the	  prevalence	  of	  pleural	  effusions	  in	  
those	  with	  and	  without	  PE.	  Although	  there	  appeared	  to	  be	  more	  patients	  with	  effusions	  
in	   the	   PE	   negative	   group	   versus	   the	   PE	   positive	   group	   (60%	   versus	   40%),	   this	   was	   not	  
significantly	  different.	  This	  was	  in	  keeping	  with	  international	  literature	  (7,	  12).	  
	  
6.4	  Pulmonary	  Hypertension	  and	  Pulmonary	  Embolism	  
A	   total	   of	   54	   patients	   (54%)	   had	   radiological	   evidence	   of	   pulmonary	   hypertension	   (as	  
indicated	   by	   a	   main	   pulmonary	   artery	   of	   greater	   than	   29mm).	   Of	   these,	   32	   were	   PE	  
negative	   and	   22	   PE	   positive.	   This	   translated	   to	   a	   66,7%	   prevalence	   of	   pulmonary	  
hypertension	  (PH)	   in	  those	  with	  PE	  (22	  out	  of	  37).	  While	  this	  study	  did	  not	  differentiate	  
between	  acute	  and	  chronic	  pulmonary	  hypertension,	  this	  is	  still	  substantially	  higher	  than	  
would	  be	  expected	  from	  combining	  the	  prevalence	  of	  both.	  The	  literature	  estimates	  the	  
prevalence	  of	  chronic	  thromboembolic	  pulmonary	  hypertension	  to	  be	  in	  the	  region	  of	  1-­‐
4%	  (11,	  51)	  and	  acute	  pulmonary	  hypertension	  from	  massive	  PE	  to	  be	  approximately	  10%	  
(52).	  
	  
However,	   that	   this	   is	   not	   a	   like	   for	   like	   comparison	   as	   these	   other	   studies	   excluded	   all	  
those	  with	   known	  previous	   confirmed	  diseases	   leading	   to	  PH.	   The	  higher	  prevalence	   in	  




PH	   predisposing	   pathology,	   which	   is	   clearly	   high	   in	   the	   sample	   population.	   	   This	   is	  
evidenced	  by	   the	   fact	   that	  even	   in	   those	  patients	  without	  PE,	  32	  out	  of	  54	   (53,3%)	  had	  
radiological	  evidence	  of	  pulmonary	  hypertension.	  	  
	  
While	  the	  frequency	  of	  pulmonary	  hypertension	  was	  ostensibly	  approximately	  13%	  higher	  
in	  the	  PE	  positive	  group	  as	  noted	  above,	  this	  was	  not	  significantly	  different.	  Moreover,	  as	  
discussed,	   the	   possibility	   of	   pre-­‐exiting	   pulmonary	   hypertension	   from	   non-­‐PE	   related	  
causes,	   has	   likely	   elevated	   the	   prevalence	   of	   PH	   in	   the	   PE	   positive	   group,	  making	   this	  
apparent	  increased	  prevalence	  even	  more	  spurious.	  	  	  
	  
6.5	  Abnormal	  Parenchymal	  Findings	  	  
CTPA	   is	   not	   only	   useful	   in	   diagnosing	   PE,	   but	   is	   also	   helpful	   in	   identifying	   parenchymal	  
findings	   that	   may	   be	   associated	   with,	   or	   be	   sequelae	   of	   pulmonary	   embolism.	  
Furthermore,	   it	   can	   also	   identify	   alternate	   pathologies	   that	   may	   mimic	   pulmonary	  
embolism.	   These	   abnormal	   parenchymal	   findings	   were	   categorised	   into	   four	   groups:	  
peripheral	   wedge-­‐shaped	   opacifications	   (likely	   indicative	   of	   pulmonary	   infarcts),	  
consolidation	  and/or	  ground-­‐glass	  opacification,	  atelectasis	  and	  masses.	  
	  
The	   overall	   frequency	   of	   parenchymal	   abnormalities	   was	   59%.	   The	   PE	   positive	   and	  
negative	  groups	  were	  virtually	   identical	   in	  terms	  of	  prevalence	  of	  parenchymal	   findings.	  
Although	  the	  overall	  figure	  is	  lower	  than	  that	  seen	  in	  similar	  studies,	  which	  were	  closer	  to	  
85%-­‐87%	   range	   (12,	   53),	   this	   is	   easily	   explained	   as	   these	   other	   studies,	   in	  





In	   terms	   of	   individual	   parenchymal	   findings,	   a	   study	   by	   Karabulut	   showed	   only	  
consolidation	  and	  wedge-­‐shaped	  opacities	  to	  be	  significantly	  associated	  with	  PE	  (12).	  In	  a	  
second	  study,	  by	  Liu	  et	  al,	  all	  of	  these	  CT	  abnormalities	  appeared	  to	  be	  more	  common	  in	  
PE	  positive	  patients,	  but	  none	  were	   found	   to	  have	  a	   statistically	   significant	   relationship	  
with	   PE	   (7).	   	   A	   third	   study	   by	   Shah	   et	   al	   (53)	   only	   showed	   a	   statistically	   significant	  	  
association	  with	  peripheral	  wedge-­‐shaped	  opacities	  and	  PE.	  
	  
This	   study	   also	   only	   found	   peripheral	   wedge-­‐shaped	   opacities	   to	   have	   a	   statistically	  
significant	   association,	   albeit	   weak,	   with	   PE.	   While	   consolidation/GGO	   and	   atelectasis	  
were	  ostensibly	  more	  common	  in	  the	  PE	  positive	  group	  and	  masses	  appeared	  to	  be	  more	  
common	   in	   the	   non	   PE	   group,	   none	   of	   these	   findings	   were	   found	   to	   be	   significantly	  
different.	  	  	  
	  
While	   the	   association	   of	   peripheral	   wedge-­‐shaped	   opacities	   (likely	   indicative	   of	  
pulmonary	  infarct)	  is	  anticipated,	  as	  it	  is	  a	  direct	  complication	  of	  pulmonary	  embolus,	  the	  
other	  findings	  may	  be	  found	  in	  a	  number	  of	  other	  conditions	  and	  their	  lack	  of	  association	  
to	   PE	   in	   various	   studies	   is	   therefore	   not	   surprising.	   It	   can	   thus	   be	   concluded	   that	  
parenchymal	   abnormalities,	   other	   than	   peripheral	   wedge-­‐shaped	   opacities,	   are	   not	  






6.6	  Risk	  Factors,	  Wells	  scores,	  D-­‐Dimer	  levels	  and	  HIV	  Status	  
There	   was	   substantial	   data	   missing	   for	   risk	   factors,	   overall	   Wells	   scores,	   and	   D-­‐dimer	  
levels.	   This	   precluded	   the	   use	   of	   comparative	   statistics.	   While	   recent	  
surgery/immobilisation	  (21%	  cases),	  and	  malignancy	  (15%)	  were	  the	  two	  most	  commonly	  
cited	   individual	   risk	   factors	   (as	   per	  Wells	   score),	   the	   lack	   of	   data	   did	   not	   allow	   for	   any	  
meaningful	  interpretation.	  	  
	  
A	  Wells	   score	  was	  only	   calculated	   in	  10	  of	   the	  100	  patients.	  Of	   these,	   three	  had	  PTED.	  
While	  two	  of	  the	  three	  had	  high	  probability	  Wells	  scores	  i.e.	  greater	  than	  four,	  the	  small	  
sample	   size	  did	  not	  allow	   for	  analysis	  of	  whether	  a	  higher	  Wells	   score	  was	   significantly	  
associated	  with	  the	  presence	  of	  PE.	  	  
	  
	  A	   total	   of	   30	  patients	  were	   reported	   to	   have	   raised	  D-­‐dimers.	  Only	   11	  of	   the	   30	  were	  
found	  to	  have	  PE.	  This	  is	  not	  surprising	  as	  D-­‐dimers	  have	  a	  low	  specificity	  for	  PE	  and	  are	  
raised	  in	  a	  number	  of	  conditions,	  including	  those	  which	  might	  mimic	  a	  PE	  such	  as	  cardiac	  
failure	  (31).	  	  
	  
As	   clinical	   decision	   rules	  make	   use	   of	   both	   D-­‐dimers	   and	  Wells	   score,	   it	   is	   relevant	   to	  
analyse	  their	  concomitant	  documentation	  as	   it	  relates	  to	  PE.	   	  Only	  3	  reports	  had	  both	  a	  
documented	  Wells	  score	  and	  a	  raised	  D-­‐dimer	  level.	  It	  is	  interesting	  to	  note	  that	  the	  two	  
that	  had	  a	  high	  probability	  of	  PE,	  as	  per	  Wells	  score,	  did	  not	  have	  a	  PE	  and	  vice-­‐versa.	  In	  
light	  of	  the	  lack	  of	  data,	  however,	  not	  much	  store	  should	  be	  placed	  on	  this	  finding.	  What	  
this	  may	  suggest,	  however,	  is	  that	  clinical	  decision	  rules	  are	  not	  routinely	  followed	  in	  the	  




optimal.	  Alternatively,	  this	  data	  may	  just	  not	  be	  included	  by	  the	  clinicians	  on	  the	  referral	  
forms.	  	  
	  
Data	   on	   HIV	   status	   was	   similarly	   absent,	   with	   only	   21	   referral	   forms	   documenting	   HIV	  
status.	  As	  HIV	  is	  in	  itself	  an	  important	  risk	  factor	  to	  PE	  and	  given	  that	  the	  local	  setting	  has	  
amongst	  the	  highest	  prevalence	  rates	  of	  HIV	  worldwide	  (54),	  it	  is	  of	  particular	  relevance.	  
This,	   however,	   likely	   relates	   more	   to	   the	   clinician	   not	   relaying	   the	   information	   on	   the	  
referral	  form,	  rather	  than	  HIV	  status	  being	  unknown,	  as	  it	   is	  commonly	  tested	  for	  in	  the	  
local	  setting.	  
	  	  
6.7	  Overall	  CTPA	  Findings	  
The	  vast	  majority	  of	   scans	   (88%)	   showed	  some	   form	  of	  CT	  abnormality	  as	  per	   the	  data	  
collected,	  which	   is	   in	  keeping	  with	  similar	   studies	   (12,	  53).	  Of	   these,	   the	  most	  common	  
finding	   was	   pulmonary	   hypertension	   (54%),	   followed	   by	   consolidation/ground-­‐glass	  
opacification	   (41%)	   and	   then	   by	   pleural	   effusions	   (40%).	   Pulmonary	   embolism	   was	  
present	  in	  37%	  of	  scans.	  Atelectasis	  (19%),	  masses	  (4%)	  and	  wedge-­‐shaped	  opacifications	  
(4%)	  were	  less	  commonly	  found.	  	  
	  
	  The	  substantially	  higher	  frequency	  of	  pulmonary	  hypertension	  is	  easily	  explained	  in	  that	  
similar	   studies	   excluded	   patients	   with	   known	   pathology	   predisposing	   to	   pulmonary	  
hypertension.	  The	  prevalence	  of	  parenchymal	  abnormalities,	  however,	  was	  in	  contrast	  to	  
studies	   by	   Shah	  et	   al	   and	   Karabulut	  et	   al	  which	   both	   found	   atelectasis	   to	   be	   the	  most	  




The	   lower	   frequency	   of	   atelectasis	   in	   this	   study	   is	   surprising	   as	   mimickers	   of	   PE	   are	  
frequently	   associated	   with	   some	   form	   of	   atelectasis	   (55),	   including	   pleural	   effusions,	  
which	  was	  in	  itself	  a	  common	  finding.	  Pleural	  effusions	  were	  evident	  in	  56%	  in	  the	  study	  
by	  Shah	  et	  al	  and	  in	  and	  43%	  of	  patients	   in	  the	  study	  by	  Karubulut	  et	  al(12),	  which	  was	  
more	  in	  keeping	  with	  the	  findings	  of	  this	  study.	  	  
	  
As	  already	  discussed,	  only	  wedge-­‐shaped	  opacities	  showed	  a	  significant	  association	  with	  
PE	   in	  the	  current	  study.	   It	   is	  therefore	  apparent	  that	  pleuro-­‐parenchymal	  abnormalities,	  
with	  the	  exception	  of	  these	  wedge-­‐shaped	  peripheral	  opacities,	  are	  of	  limited	  value	  when	  
assessing	  for	  PE	  on	  CTPA.	  The	  same	  remains	  true	  for	  radiological	  evidence	  of	  pulmonary	  
hypertension.	  
6.8	  Possible	  Limitations	  of	  the	  Study	  	  
The	  study	  had	  a	  number	  of	  possible	  limitations:	  
	  
•  Lack	  of	  data	   -­‐	  being	  retrospective	   in	  design,	  not	  all	   the	  data	   that	   the	  researcher	  
wished	  to	  collect	  was	  available.	  This	  was	  particularly	  true	  for	  Wells	  score,	  D-­‐dimer	  
levels	  and	  HIV	  status.	  	  
•  Missing	  data	  –	  as	  per	  4.6	  certain	  assumptions	  needed	  to	  be	  made	  with	  respect	  to	  
missing	  data.	  Of	  particular	  note	   is	  the	  assumption	  that	   if	  the	  presence	  of	  pleural	  
effusions	  were	  not	  mentioned	  in	  the	  report,	  it	  was	  deemed	  to	  be	  absent.	  This	  was	  
based	   on	   the	   fact	   that	   this	   finding	   is	   easily	   identified	   and	   generally	   noted.	  
However,	  as	  the	  researcher	  did	  not	  review	  the	  reports	  himself,	  there	  is	  room	  for	  
error.	  	  
•  Interobservor	   variability	   -­‐	   the	   completeness	   and	   accuracy	   of	   the	   radiological	  
reports	   may	   vary	   depending	   on	   the	   level	   of	   expertise	   and	   experience	   of	   the	  




only	   using	   consultant	   radiologist	   reports,	   even	   among	   consultants,	   some	  
variability	  may	  exist.	  	  
•  Lack	  of	  external	  validity	  –	  as	  this	  is	  a	  single	  centre	  study,	  the	  results	  and	  findings	  
may	  not	  be	  generalizable	  to	  the	  population	  at	  large.	  	  
6.9	  Future	  Applications	  
6.9.1	  Referral	  template	  and	  radiological	  care	  pathway	  	  	  
It	  is	  apparent	  from	  this	  study	  that	  there	  is	  a	  lack	  of	  information,	  particularly	  with	  respect	  
to	  Wells	   score,	  D-­‐dimer	   level	   and	  HIV	   status.	   This,	   in	   turn,	  may	   suggest	   a	   low	  usage	  of	  
clinical	  decision	   rules,	  which	  will	   inevitably	   result	   in	  unnecessary	   referrals	   for	  CTPA	  and	  
increased	   patient	   risk.	  Moreover,	   unnecessary	   investigations	   further	   burden	   an	   already	  
over-­‐utilised	  and	  under-­‐resourced	  public	  health	  sector.	  
	  
This	  has	  led	  the	  researcher	  to	  create	  a	  referral	  template	  (See	  Appendix	  C),	  with	  a	  view	  to	  
alleviating	  the	  above-­‐mentioned	  issues.	  This	  template	  outlines	  the	  necessary	  inputs	  that	  
the	   clinician	   should	   specify.	   The	   referral	   template	   expands	  on	   the	   conventional	   patient	  
information	  sticker,	  which	  typically	  only	  contains	  patient	  name,	  demographic	  details	  such	  
as	   age	   and	   gender,	   and	   the	   hospital	   number.	   The	   template	   also	   incorporates	   D-­‐dimer	  
levels	  and	  Wells	  score,	  features	  of	  clinical	  presentation	  and	  provides	  space	  to	  enter	  other	  
relevant	  information.	  This	  includes	  specifying	  other	  known	  risk	  factors,	  which	  may	  not	  be	  
included	   in	  Wells	   score,	   such	   as	   connective	   tissue	   diseases	   and	   clotting	   abnormalities.	  
Moreover,	  information	  with	  respect	  to	  relevant	  previous	  imaging,	  which	  is	  of	  paramount	  





The	  timing	  of	  this	  application	  is	  fortuitous,	  as	  the	  department	  of	  radiology	  at	  CMJAH	  has	  
just	  gone	  live	  with	  a	  Picture	  Archiving	  and	  Communication	  System	  (PACS),	  which	  will	  be	  
linked	   to	   the	   Radiological	   Information	   System	   (RIS)	   and	   ultimately	   to	   the	   Hospital	  
Information	  System	  (HIS).	  While	  a	   lengthy	  explanation	  of	  what	  PACS,	  RIS	  and	  HIS	  are,	   is	  
beyond	  the	  scope	  of	  this	  research,	  the	  point	  is	  that	  the	  implementation	  of	  this	  technology	  
will	  allow	   for	  control	  of	  both	   inputs	  and	  outputs.	  Furthermore,	  previous	   imaging	   (along	  
with	  reports)	  can	  easily	  be	  accessed.	   In	  terms	  of	   inputs,	  the	  patient	  sticker	   information,	  
Wells	   score	   and	   D-­‐dimer	   values	   can	   be	   made	   mandatory,	   while	   other	   pertinent	  
information	  such	  as	  HIV	  status,	  clinical	  presentation	  and	  other	  risk	   factors	  can	  have	  the	  
option	   for	   data	   inputs	  where	   available.	   This	   information	   can	   then	   feed	   a	   pre-­‐designed	  
clinical	   decision	   rule,	   which	   algorithmically	   determines	   the	   radiological	   (and	   even	  





Figure	  6.1	  2014	  European	  Society	  of	  Cardiology	  guidelines	  on	  the	  diagnosis	  and	  management	  of	  acute	  pulmonary	  embolism(56)	  
	  
The	  above	  algorithm	  can	  be	  further	  modified	  to	  suggest	  chest	  radiography	  as	  a	  first-­‐line	  
investigation.	   While	   chest	   radiographs	   are	   relatively	   insensitive	   to	   the	   diagnosis	   of	   PE	  
(57),	  they	  are	  useful	  in	  identifying	  mimickers	  of	  PE	  as	  well	  as	  in	  aiding	  the	  interpretation	  
of	   V/Q	   scans.	   Furthermore,	   chest	   radiographs	   have	   lower	   radiation,	   lower	   cost	   and	  
increased	  ease	  and	  convenience	  of	  use	  when	  compared	  to	  a	  CT	  scan.	  	  	  
	  
Similarly	   the	   pathway	   can	   incorporate	   suggesting	   V/Q	   scans	   as	   an	   alternative	  
investigation	   in	  appropriate	   settings.	  These	   include	  patients	  with	   renal	  dysfunction	   that	  
prohibit	   the	   use	   of	   contrast	   agents	   and	   young	   female	   patients	  where	   there	   is	   concern	  
over	   breast	   radiation.	   It	   is	   also	   useful	   as	   an	   alternate	   investigation	   in	   non-­‐diagnostic	  
CTPAs.	  	  
	  
6.9.2	  Reporting	  Template	  
CTPA	  reports	  are	  not	  standardised,	  which	  results	  in	  inconsistent	  and	  at	  times	  absent	  data.	  
This	  not	  only	  impacts	  the	  quality	  of	  the	  report	  and	  by	  association	  service	  delivery	  to	  the	  
clinician,	   but	   also	   reduces	   the	   ability	   to	   perform	   research.	   As	   such,	   the	   researcher	   has	  
created	   a	   reporting	   template	   (See	   Appendix	   D),	   which	   provides	   the	   radiologist	   with	   a	  
quick,	  easy	  to	  use	  checklist.	  It	  can	  similarly	  be	  embedded	  into	  the	  PACS	  and	  RIS	  system,	  so	  





While	  its	  design	  and	  content	  is	  fed	  by	  existing	  templates	  such	  as	  the	  Radiological	  Society	  
of	   North	   America	   (RSNA)	   CTPE	   template	   (58),	   it	   has	   been	   substantially	   enhanced	   and	  
modified.	   These	   changes	   not	   only	   incorporate	   relevant	   elements	   derived	   from	   the	  
literature	  review	  and	  this	  study,	  but	  also	  from	  the	  day-­‐to-­‐day	  experience	  and	  knowledge	  
of	  the	  author	  who	  is	  a	  Fellow	  of	  the	  College	  of	  Radiologists	  of	  South	  Africa.	  
	  
The	   checklist	   covers	   salient	   information	   with	   respect	   to	   the	   PE	   itself,	   as	   well	   as	  
complications	   and	   associated	   and/or	   alternate	   findings.	   It	   breaks	   it	   systematically	   into	  
information	   around	   the	   embolus	   itself,	   then	   into	   the	   key	   vascular	   complications,	   viz.	  
pulmonary	  arterial	  hypertension	  and	  by	  extension	  right	  ventricular	  strain.	   It	  then	  moves	  
on	   to	   pleural	   complications/findings	   followed	   by	   parenchymal	   findings	   and	   then	  
progresses	  to	  the	  general	  findings	  a	  reader	  needs	  to	  look	  at	  when	  reviewing	  a	  CT	  chest	  of	  
any	   nature.	   It	   does	   assume	   some	   baseline	   radiological	   knowledge	   for	   e.g.	   that	   the	  
pulmonary	  artery	  trunk	  is	  measured	  at	  the	  bifurcation,	  and	  that	  the	  reader	  understands	  
how	   to	   characterise	  a	  mass,	  but	   is	  extensive	  enough	   to	  provide	  a	   fairly	   full	   checklist	   to	  
guide	  a	  junior	  registrar	  and	  to	  remind	  a	  more	  senior	  interpreter.	  
	  
6.9.3	  Future	  research	  	  
This	   study,	   both	   through	   its	   limitations	   and	   findings	   gives	   rise	   to	   a	   number	   of	   future	  
research	  opportunities,	  particularly	  around	  the	  first	  3	  objectives.	  These	  include:	  
	  
• Yield	  –	  relating	  to	  the	  higher	  yield	  rate	  of	  PE	  positive	  patients	  in	  this	  study	  when	  




might	   relate	   to	   higher	   frequency	   due	   to	   increased	   HIV/TB	   prevalence.	   Another	  
possible	  causative	  factor	  could	  be	  overcalling	  by	  the	  radiologist.	  This	  lends	  itself	  to	  
the	  following	  research	  opportunities:	  	  
o 	  Comparative	  analysis	  of	  the	  prevalence	  of	  PE	  in	  South	  Africa	  in	  HIV	  and/or	  
TB	  infected	  and	  non-­‐infected	  patients	  respectively	  
o 	  	  Interobservor	  variability	  in	  assessing	  PE	  on	  CTPA	  	  
• Pleural	   effusions	   	   -­‐	   relating	   to	   lower	   prevalence	   and	   different	   characteristics	   of	  
pleural	   effusions	   in	   the	   PE	   positive	   group	   in	   this	   study,	   which	   show	   stark	  
differences	  with	   respect	   to	   the	   international	   literature.	   An	  opportunity	   exists	   to	  
analyse	  the	  following:	  
o Ethnic	  differences	  in	  the	  prevalence	  of	  pleural	  effusion	  in	  the	  local	  setting	  
o Characteristics	  of	  pleural	  effusions	  in	  PE	  positive	  patients	  	  
• Pulmonary	   hypertension	   –	   the	   significantly	   higher	   frequency	   of	   pulmonary	  
hypertension	  in	  this	  study,	  compared	  to	  other	  similar	  studies,	  likely	  relates	  to	  not	  
excluding	   patients	   with	   known	   conditions	   predisposing	   to	   pulmonary	  
hypertension	   (PH).	   A	   study	   using	   this	   exclusion	   criteria	   could	   be	   performed	   in	  
order	  to	  compare	  like	  with	  like:	  
o Frequency	   of	   pulmonary	   hypertension	   in	   patients	   with	   no	   known	  






Pulmonary	   thromboembolic	   disease	   (PTED)	   is	   a	   common	   clinical	   entity,	  with	   significant	  
morbidity	  and	  mortality.	  However,	  due	  to	  its	  relatively	  non-­‐specific	  symptoms,	  pulmonary	  
embolism	  remains	  a	  challenge	  to	  diagnose.	  This	  has	   led	  to	  apparent	   increasing	  referrals	  
for	  CTPA	  and	  decreasing	  yield	  rates	  raising	  concern	  for	  patient	  safety.	  	  
	  
Part	  of	   the	  diagnostic	   challenge	  alluded	   to	  above,	   is	   the	  myriad	  of	   causes	  of	   symptoms	  
that	  may	  mimic	   pulmonary	   embolism	   (PE).	   There	   are	   a	   number	   of	   pleuro-­‐parenchymal	  
abnormalities	  that	  may	  be	  visualised	  on	  CTPA	  that	  could	  account	  for	  these	  symptoms.	  Of	  
particular	  interest,	  is	  pleural	  effusion.	  Pulmonary	  embolism	  is	  an	  under-­‐recognised	  cause	  
of	   pleural	   effusion,	   and	   delay	   in	   therapy	   may	   cause	   an	   increase	   in	   morbidity	   and	  
mortality.	   Pleural	   effusions	   as	  mentioned,	   however,	   are	   not	   the	   only	   abnormal	   finding,	  
and	  this	   led	   the	  researcher	   to	   further	   interrogate	   the	   frequency	  and	  association,	   if	  any,	  
that	  these	  findings	  may	  have	  with	  PE.	  	  
	  
In	   light	   of	   the	   above,	   this	   study	   assessed	   the	   diagnostic	   yield	   in	   patients	   at	   Charlotte	  
Maxeke	   Johannesburg	   Academic	   Hospital	   undergoing	   CTPA	   for	   suspected	   PTED	   and	  
documented	   the	  occurrence	  of	  pleural	  effusion,	  pulmonary	  hypertension	  and	  abnormal	  
parenchymal	  chest	  findings	  in	  patients	  with	  and	  without	  documented	  PTED.	  It	  also	  sought	  
to	  capture	  relevant	  clinical	  and	  biochemical	  parameters	  such	  as	  risk	  factors,	  Wells	  Score,	  





While	  similar	  studies	  have	  been	  done	  internationally,	  there	  is	  a	  dearth	  of	  literature	  in	  the	  
local	  setting.	  South	  Africa	  provides	  a	  markedly	  different	  environment,	  including	  inter	  alia	  
higher	  HIV/AIDS	  and	  TB	  prevalence	  (both	  of	  which	  are	  independent	  risk	  factors	  for	  PTED),	  
distinctive	   demographic	   profile	   and	   in	   many	   cases,	   a	   more	   constrained	   and	   over-­‐
burdened	  public	  sector.	  It	  is	  therefore	  the	  hope	  of	  the	  researcher	  that	  the	  findings	  of	  this	  
research	   provides	   information	   which	   will	   assist	   the	   clinician	   in	   his	   referral	   process,	  
enhance	   the	   quality	   of	   the	   radiological	   service	   provided	   and	   streamline	   the	   process	   in	  
general.	  	  
	  
As	  an	   in-­‐depth	  discussion	  of	   results	   is	  provided	   in	  chapter	   six,	  only	   the	  key	   findings	  are	  
mentioned	  here.	  There	  were	  two	  primary	  objectives:	  yield	  rate	  and	  frequency	  of	  pleural	  
effusions.	  	  
	  
• Yield	  -­‐	  A	  diagnosis	  of	  pulmonary	  embolism	  was	  confirmed	  in	  37	  cases	  (37%).	  	  The	  yield	  
rate	   compared	   favourably	  with	   other	   studies,	   and	  while	   this	  may	   be	   due	   to	   better	  
clinical	  assessment,	  other	  causes	  that	  could	  contribute	  to	  this,	  include	  inter	  alia	  higher	  
HIV/AIDS	  and	  TB	  prevalence,	  and	  possible	  overcalling	  by	  the	  radiologist.	  	  	  
• The	   frequency	   of	   pleural	   effusions	   -­‐	   Overall	   40	   patients	   (40%)	   had	   an	   identifiable	  
pleural	  effusion	  on	  CTPA.	  Of	  the	  60	  patients	  with	  no	  pulmonary	  embolism,	  26	  (43,3%)	  
had	  pleural	   effusions.	  A	   total	  of	  14	  patients	  out	  of	  40	  patients	   (37,8%)	  with	  PE	  had	  
pleural	  effusions.	  .	  	  There	  was	  no	  significant	  differences	  in	  frequency	  in	  those	  with	  and	  
without	  PTED.	  The	  frequency	  of	  pleural	  effusions	  was	  lower	  than	  that	  quoted	  in	  other	  
studies	   and	   showed	   somewhat	   different	   characteristics	   to	   those	   typically	  




by	   the	   literature)	   and	   the	   characteristics	   may	   merely	   be	   as	   a	   result	   of	   the	   small	  
amount	  of	  available	  data	  in	  this	  regard.	  
	  
In	   terms	   of	   the	   secondary	   objectives,	   pulmonary	   hypertension	   was	   present	   in	   54%	   of	  
cases	  with	   no	   significant	   difference	   between	   the	   PE	   positive	   and	   negative	   groups.	   This	  
was	  a	   far	  greater	  proportion	  of	  cases	  when	  compared	  to	  other	  studies.	  However,	  other	  
studies	   excluded	   patients	   with	   pre-­‐existing	   conditions	   that	   may	   cause	   pulmonary	  
hypertension,	  which	  would	   account	   for	   the	   difference.	   Abnormal	   parenchymal	   findings	  
were	   a	   common	   finding,	   with	   59%	   of	   cases	   showing	   at	   least	   one	   parenchymal	  
abnormality.	  This	  was	  not	  unanticipated	  due	   to	   the	  number	  of	  PE	  mimickers	  discussed.	  	  
The	   most	   common	   parenchymal	   finding	   was	   consolidation/ground-­‐glass	   opacification	  
(41%),	  followed	  by	  atelectasis	  (19%).	  Wedge-­‐shaped	  opacification	  and	  masses	  both	  had	  a	  
prevalence	   of	   4%.	   Overall,	   only	   peripheral	   wedge-­‐shaped	   opacities	   had	   an	   association	  
with	  pulmonary	  emboli.	  This	  finding	  is	  not	  without	  merit,	  as	  the	  other	  abnormalities	  are	  
commonly	   found	   in	   a	   number	   of	   other	   conditions,	   whereas	   peripheral	   wedge-­‐shaped	  
opacities	  in	  this	  case	  likely	  indicate	  pulmonary	  infarct,	  the	  most	  common	  cause	  of	  which	  
is	  PE.	  	  
	  
While	  not	   a	  defined	  objective,	   it	  was	   also	   clear	   that	   the	   referral	   form	   seldom	  provided	  
information	  with	  respect	  to	  individual	  risk	  factors	  (as	  per	  Wells	  score),	  overall	  Wells	  score,	  
D-­‐dimer	  levels	  and	  HIV	  status.	  While	  these	  may	  merely	  be	  omissions	  on	  the	  form,	  it	  may	  





It	  can	  therefore	  be	  concluded	  that	  pleuro-­‐parenchymal	  abnormalities,	  with	  the	  exception	  
of	  peripheral	  wedge-­‐shaped	  opacities,	  as	  well	  as	  evidence	  of	  pulmonary	  hypertension	  are	  
of	  limited	  value	  when	  assessing	  for	  PE	  on	  CTPA.	  	  
	  
As	  with	  most	  research,	  the	  findings	  themselves	  are	  not	  the	  only	  benefit	  of	  the	  study,	  but	  
much	  is	  also	  gained	  through	  the	  analyses	  and	  interpretation	  of	  the	  results.	  Moreover,	  the	  
further	  questions	  it	  catalyses	  and	  future	  research	  opportunities	  it	  presents,	  is	  what	  drives	  
growth	  of	  the	  current	  knowledge	  base.	  	  This	  study	  was	  no	  different.	  	  
	  
The	  researcher	  used	  the	  findings	  to	  not	  only	   identify	   further	  research	  opportunities	  but	  
also	   to	   create	   a	   referral	   and	   reporting	   template	   that	   will	   hopefully	   alter	   the	   entire	  
radiological	   care	   pathway,	   pro-­‐actively	   assisting	   both	   the	   clinician	   in	   his/her	   referral	  
patterns	   for	   CTPA	   and	   similarly	   giving	   guidance	   to	   the	   radiologist,	   thereby	   improving	  
his/her	  service	  delivery.	  
	  
It	   is	   clear	   that	   diagnosis	   of	   pulmonary	   embolism	   is	   fraught	  with	   difficulty	   starting	  with	  
clinical	   diagnosis,	   through	   to	   determining	   the	   appropriate	   investigations	   and	   then	  
interpreting	   the	  many	  additional	  or	  alternate	   radiological	   findings.	   It	   is	   the	   researcher’s	  
wish	  that	  this	  study	  will	  in	  some	  way	  contribute	  to	  creating	  a	  more	  efficient	  and	  effective	  
radiological	  pathway	  for	  suspected	  pulmonary	  embolism,	  that	  not	  only	  improves	  patient	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